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ABSTRACT 
Several dominant mutations at the agouti locus in the mouse cause a syndrome of 
adult-onset obesity, hyperinsulinemia, and insulin resistance. Although ectopic 
overexpression of the agouti gene is directly responsible for the disease in these mutations, 
the precise mechanism is unclear. Intracellular Ca2+ ([Ca2+]i) appears to have a role in 
mediating insulin signal transduction, and altered handling of [Ca2+]i homeostasis and flux 
is observed in obese and insulin resistant animals and humans. Data reported here 
demonstrate that mice carrying the dominant agouti mutation, viable yellow (A'), exhibit 
an elevation of [Ca2+]i and Ca2+ influx rate in insulin-sensitive type I skeletal muscle. The 
degree of elevation in [Ca2+]i is highly correlated with the degree of expression of agouti 
gene and the elevation of body weight. Moreover, recombinant agouti protein directly 
induced a sustained increase in [Ca2+]i in cultured myocytes and adipocytes; this effect is 
substantially inhibited by Ca2+ channel blockade. Ca2+ channel blockade was also effective 
in reducing fat pad mass and fatty acid synthase (FAS) mRNA levels and activity in 
adipocytes of transgenic mice expressing the agouti gene in a ubiquitous manner. These 
results are consistent with previous reports in which recombinant agouti protein directly 
stimulates FAS mRNA levels and activity and triglyceride content in cultured adipocytes 
in a Ca2+ dependent manner. Accordingly, altered [Ca2+]i metabolism appears to be 
involved in development of obesity syndrome in Avy mice, and this defect in Ca2+ signaling 
may cause activation of FAS either directly or indirectly and subsequent de novo 
lipogenesis, contributing accumulation of fat depot in these mice. 
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PARTl 
INTRODUCTION 
1 
INTRODUCTION 
Dominant mutations at the murine agouti locus, including viable yellow (A"'), lead 
to ectopic expression of the agouti gene and result in mice which are characterized by a 
predominantly yellow coat color and metabolic derangements including obesity, 
hyperinsulinemia and insulin resistance (1, 2}. The mouse agouti gene normally regulates 
differential pigment production in melanocytes (3). This agouti regulation of pigment 
production is mediated by competitive antagonism of a-melanocyte-stimulating-honnone 
binding to its receptor in melanocytes, resulting in suppression of cAMP production and 
consequent shift from eumelanin (black) to phaeomelanin (yellow) production in 
melanocytes ( 4 ). However, the mechanism linking this pigmentation gene to development 
of the obesity syndrome has not yet been identified. 
Obesity is generally associated with hyperinsulinemia and insulin resistance (5-10). 
Although the precise mechanism for this insulin resistance is poorly understood, several 
studies have indicated a potential role for Ca2+ in mediating insulin signal transduction ( 11-
19) and that insulin regulates intracellular free Ca2+ ([Ca2•]i) (20, 21 ). An optimal range 
of [ Ca2+]i for maximizing insulin action has been demonstrated, such that increasing 
[ Ca2+]i beyond this range results in attenuation of insulin-stimulated glucose uptake in 
both human and rat adipocytes (21 ). In support of this concept, obese and insulin resistant 
patients exhibit higher basal [Ca2+]i in adipocytes than normal individuals, and Ca2+ channel 
blockade decreases [Ca2+]i and improves insulin sensitivity in these subjects (22). 
Consequently, this study investigated; ( 1) whether the dominant agouti mutation, 
A"", exhibits altered [Ca2+]i metabolism in insulin sensitive tissue(s); (2) whether 
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recombinant agouti protein directly influences [Ca2+]i in insulin sensitive cells in culture; 
(3) whether melanocortin receptors play a role in agouti-mediated Ca2+ signaling; (4) 
whether Ca2+ channel antagonism attenuates agouti-induced activation of fat storage and 
ameliorates insulin resistance in mice overexpressing the agouti gene. 
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I. PHYSIOLOGICAL OBSERVATIONS IN THE YELLOW MOUSE 
The agouti locus is one of several genetic loci that regulate pigmentation in 
mammals. The agouti locus in chromosome 2 in the mouse controls the alternating 
production of pigment granules, eumelanin (black) and phaeomelanin (yellow}, that are 
deposited in growing hairs ( I ). The wild-type agouti mouse produces both eumelanin and 
phaeomelanin within the same hair bulb melanocytes, in a sequential manner. The 
sequence of pigmentation during hair growth is such that eumelanin is deposited in the tip 
of the newly forming hair and then phaeomelanin is deposited for a short time, during the 
period of time when the hair is growing most rapidly (2, 3 ). The melanocytes then switch 
back to eumelanin production for the remainder of the period of hair formation, resulting 
in agouti coloration of black with a subapical band of yellow. Nineteen different alleles 
have been identified at the agouti locus, resulting in an intricate dominance hierarchy in 
which alleles associated with phaeomelanin production are generally dominant over alleles 
associated with eumelanin production (4). 
Lethal yellow (A') is the most dominant of the agouti locus alleles, and results in a 
uniformly yellow coat. The second most dominant allele in the agouti hierarchy is called 
viable yellow (A"); interestingly, this mutant allele results in extremely variable coat colors 
ranging from totally yellow through all degrees of intermixtures of yellow, black, and 
agouti to totally agouti. Next to yellow fur, these dominant agouti mutations are 
particularly interesting because they result in mice that exhibit obesity, hyperinsulinemia, 
and non-insulin-dependent diabetes. 
7 
A. Obesity 
I .  Hyperphasia and efficiency of food utilization 
Between 3 and 4 weeks of age, yellow mice start showing weight divergence with 
their non-yellow littermates; they continue to gain weight at a more rapid rate, reaching a 
maximum plateau at about the 7 months of age (5, 6). Young yellow obese mice are 
hyperphagic, while after 40 days of age yellow mice significantly exceeded their black 
littermates in weight gain with only moderate increase in food consumption, indicating a 
greater metabolic efficiency in converting food energy to body fat (7, 8). Accordingly, 
unlike mice with hypothalamic obesity, hyperphasia does not appear to be the major 
mechanism of obesity in the dominant agouti mutations. 
2. Lipogenesis, triglyceride content, and lipolysis 
Yellow mice exhibit characteristics of maturity-onset type obesity (9). Early in 
life, they do not have higher lipogenesis rates and have only a moderate increase in carcass 
and liver triglyceride content (9). However, when they reach maturity, their lipogenesis 
rate does not demonstrate the normal maturity-related decrease in lipogenesis (9). This is 
in contrast to other obese mouse models, such as obese (ob/ob) and diabetes (db/db) that 
have characteristics of juvenile type obesity, in which higher lipogenesis rates and a greater 
accumulation of triglyceride occur when they are young (9). Indeed, lipogenesis at 
maturity is normal in ob/ob and db/db mice (9). Furthermore, hepatic lipogenesis in AV>'/a 
mice is much lower than that of ob/ob and db/db mice at corresponding ages (9). The 
total triglyceride content in the mature male yellow mice is increased approximately 4-fold 
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( to approximately 25 % of body weight) compared with black controls, while mature male 
ob/ob and db/db mice have 40 % and 50 % body fat, respectively (9). 
Adipocyte number in adult yellow mice is not significantly different from control 
values, although the adipocytes are significantly larger cells than in lean controls ( 1 0). The 
enlargement of these adipocytes is a response to the internal milieu, since transplantation 
of adipose tissue from fat (A'la) to lean (ala) mice or vice versa is followed by acquisition 
of anatomic characteristics similar to the host ( 1 1  ). In contrast, ob/ob mice have both a 
significantly larger number and size of adipocytes than controls, proposing a classification 
for genetic obesity based primarily upon the cellular characteristics of the adipose depots 
( 10). 
With regard to lipolysis, the basal and agonist stimulated lipolytic rate of adipose 
tissue isolated from yellow AV1/a mice is approximately 50 % lower than that of black ala 
mice ( 12). As in other obese animals, including ob/ob and db/db mice, however, the 
lipolytic response of AV1/a adipose tissue to dibutyryl cyclic AMP is normal, suggesting 
reduced cAMP signaling mechanisms in adipocytes from these mice ( 12, 1 3). 
3. Effect of diet and activity 
Yellow mice are sensitive to dietary fat content, with weight gain resulting 
primarily from an increase in energy efficiency (8). Fenton et al. ( 14) found that feeding a 
high fat diet caused obesity even in highly inbred yellow mice that did not become 
markedly overweight in standard conditions. Similarly, Carpenter et al. ( 1 5) found that 
yellow mice gained more weight on high-fat diets than on high-carbohydrate or high-
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protein diets. Exercise in squirrel-type cages significantly reduced body weight in yellow 
adult mice without a significant difference in non-obese mice ( 1 5). 
4. Thermogenesis 
Increased efficiency of energy utilization may result from a defect in the regulation 
ofthermogenesis ( 16- 1 8). There is evidence of disturbed temperature regulation in A">' 
obese yellow mice; at low environmental temperatures, the mean rectal temperature of 
obese mice continued to fall during a one-hour exposure, while that of normal mice fell 
only during the first 10  minutes and plateau ( 19). Thus, A">' mice exhibit a clear defect in 
adaptive thermogenesis. However, their hypothermia is not sufficient to account for their 
being overweight, as their weight loss induced by food restriction does not result in 
increased thermogenesis (20). 
5. Endocrine status 
Early work by Weitze, in 1940, first showed evidence for hormonal involvement in 
the development of obesity in yellow mice (2 1 ). Yellow mice parabiosed with non-yellow 
mice did not become obese, suggesting that adiposity in yellow mice is caused by a 
hormonal disorder (2 1). However, Wolff (22) could not confirm the findings, and instead 
noted that parabiosis of yellow and black littennates for six months failed to affect body 
weight or composition in either group. 
Conflicting results have been reported after hypophysectomy. At 45-50 days of 
age, hypophysectomy decreased weight gain both in yellow (A"la) and black (a/a) mice 
compared to sham-hypophysectomized mice (23 ). However, hypophysectomized yellow 
(A"la) mice still gained more weight than hypophysectomized black (a/a) siblings and 
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exhibited an excessive accumulation off at, thereby demonstrating that the pituitary 
mediated regulatory pathways are not primarily involved in the mechanism of obesity in 
yellow mice (23). Similarly, Salem et al. (24) found that hypophysectomized yellow 
(A""IA) mice still showed more than a 4-fold increase in parametrial fat pad compared to 
non-operated agouti (A/A) controls. However, they also observed a drastic decrease in 
body weight and insulin resistance in hypophysectomized yellow mice, suggesting a 
potential role for the pituitary gland in the maintenance of obesity in yellow mice. 
However, hypophysectomized control mice were not studied for comparison. 
The obesity of yellow mice does not appear to be due to deficiencies of growth 
hormone or thyrotropin. When the yellow obese. mice gene (A") is transferred to the dwarf 
mouse (dwldw), which congenitally lacks growth hormone, the yellow dwarf (A1/a dwldw) 
mice still develop obesity to become fat little mice and their growth rate responded to 
growth hormone administration to a similar degree as the black dwarf (a/a dwldw) mice, 
implying that growth hormone is not necessary for the expression of the obesity (25). 
The role of adrenal hormones in the development of obesity in yellow mice is also 
controversial. It has been demonstrated that in yellow A""la or A1/a mice, plasma 
corticosterone levels were similar with those in black (ala) mice (26), although 
corticosterone levels were elevated in A""la mice in another study (27). Adrenalectomy 
produced a 30- 33 % reduction in fat deposition in both yellow (A1/a) and black (ala) 
mice, but adrenalectomized yellow mice still had a larger percent of body lipid 
composition and were fatter than adrenalectomized black mice seven months after surgery 
(28). Shimizu et al. (27) demonstrated that adrenalectomy significantly reduced the 
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weight gain in both yellow obese (A"'la) and lean black (ala) mice thirty-two days after 
the operation; this effect was especially prominent in the adrenalectomized yellow mice, 
where the gain in body weight decreased to almost the same level as in the sham-operated 
controls. 
An increase in circulating insulin levels is exhibited in yellow obese A1/- and A"'/­
mice at approximately 6 weeks of age, when the animals become overtly obese (29)� db/db 
mice are hyperinsulinemic at IO  days of age (30) and hyperinsulinemia in ob/ob mice is 
detectable by 4 weeks of age (31 ). At 6 months of age, when the obesity of yellow A"' la 
mice peaks, plasma insulin level is more than 20 fold that of black ala in both male and 
female (32). Hyperinsulinemia may be essential for the expression of the obesity since 
pseudoagouti (A"'la), which are phenotypically agouti, mice have normal plasma insulin 
and fail to gain weight, whereas phenotypically yellow (A"'la) mice have high plasma 
insulin and become obese (33). However, the role of insulin in obesity in yellow A"'!- mice 
is not clear (34). 
B. Carbohydrate metabolism 
I .  Hyperglycemia 
Fed yellow obese mice have higher blood glucose concentrations than non-obese 
controls (24, 35), whereas fasted yellow obese have normal blood glucose values (24, 16). 
Blood glucose changes in response to cortisone, adrenocorticotropic hormone, growth 
hormone, and glucagon is exaggerated in yellow obese mice when compared to normal 
controls (16). Plasma glucose level of yellow (A"'IA) exhibit a sexual dimorphism in that 
males are hyperglycemic and most females are either normoglycemic (29) or only mildly 
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hyperglycemic (32). Indeed, this gender difference was also exhibited in plasma insulin 
concentration; compared to that in the yellow males, the plasma insulin concentration in 
yellow females began to increase above the nonnal agouti values at a later time and to a 
lesser extent (29). Further, glucose tolerance of Avyla males is more impaired than that of 
female Avyla mice (29). However, administration of dexamethasone overwhelmed the 
protective mechanism against hyperglycemia in female viable yellow mice and induced 
hyperglycemia (36). 
Several glucose tolerance determinations in AvylA mice of various ages (3-8 
months) have shown that tolerance to glucose remains impaired in spite of the very high 
plasma insulin values ( 400-500 µUlmL), an indication of an insulin resistant condition 
(29). In addition, adipose tissue from AvylA mice required more insulin to stimulate 
glucose oxidation than in Ala mice, verifying that yellow AvylA mice are less sensitive and 
less responsive to insulin than Ala mice (29). 
Ciglitazone ( 5-[ 4( 1 -methylcyclohexylmethoxy )benzyl]thiazolidine-2, 4-dione ), a 
compound known to improve insulin sensitivity, improved glucose tolerance in the 
presence of exogenous insulin in yellow Avyla mice (32). Ciglitazone also prevented and 
reversed dexamethasone-induced hyperglycemia in female viable yellow mice (36). 
2. Pancreatic islet hyperplasia and hypertrophy 
Hypertrophy and hyperplasia of the islets of Langerhans are consistent features 
observed in pancreata of yellow obese mice (37). The pancreatic islets of the 6-month-old 
male yellow mice were characterized by considerable capillary dilation, with deregulation 
and increased nuclear size of the f3-cells and a concomitant increase in total islet volume 
1 3  
(35). This increased total volume of the hyperplastic islet tissue in the yellow obese mice 
may reflect the adaptation of the P-cells to increased insulin demand (35). It has been also 
reported that increased P-cell proliferation occurs between 14 and 21  days of age in 
yellow A'VY/A, prior to any detectable hyperinsulinemia, indicating morphological changes 
precede biochemical changes in pancreatic islets (38). 
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II. MOLECULAR BASIS OF GENETIC OBESITY IN RODENTS 
A. Obese mouse (ob/ob) 
The obese (ob) gene in the mouse chromosome 6 is specifically expressed in white 
adipose tissue and encodes a 4.5-kb mRNA with a 167 amino acid open reading frame. 
The predicted polypeptide is largely hydrophilic and contains a putative N-terminal signal 
sequence (39). The ob mutation is autosomal recessive and results in mice that exhibit a 
juvenile-onset obesity and type II diabetes (reviewed in refs. 40, 4 1  ). The mutant allele in 
C57BU6J ob/ob mice causes a nonsense mutation resulting from a single base substitution 
(C � T) in coding sequences that results in a change of an arginine to a stop condon (39). 
Northern analysis reveals that two different ob mutant strains exhibit a different level of 
ob mRNA expression in adipose tissue; C57BIJ6J ob/ob mice exhibit overexpression 
while SM/Ckc-+ Dae ob21/ob21 mice do not express. However, the molecular mechanisms 
leading the altered expression in those mutations are under investigation (39). 
The working hypothesis for obese action is that a circulating protein-based signal, 
generated in adipose tissue, acts on central neuronal networks and plays a role in the 
regulation of feeding behavior and energy balance. 
The human homologue of the mouse ob gene has an 84 % amino acid sequence 
homology with extensive signal sequence identity in the N-terminus of the mature protein 
(39). 
Several studies have characterized the ob gene product, which has been named 
leptin, as a circulating signal for the regulation of body weight. Peripheral or central 
supply of the mouse recombinant leptin reduces food intakes, body weight, serum glucose 
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and insulin, and increases metabolic rate and body temperature in ob/ob mice (42-44). 
Human recombinant leptin also reduces body weight, body fat, and plasma glucose in 
ob/ob mice (43). 
The mouse OB protein is found from normal mouse plasma, but not in plasma 
from C57BU6J ob/ob mice; similarly, the human OB protein is present in plasma from 
normal humans, suggesting that the OB protein serves an endocrine function to regulate 
body fat store (43). In contrast, obese humans and rodents (other than ob/ob mice) are 
not defective in their ability to produce leptin mRNA or protein and generally produce 
higher levels than lean individuals ( 45). 
The receptor for leptin, OB-R, has recently been characterized and appears to be a 
single membrane-spanning receptor with 8 1 6  amino acids extracellular domain followed 
by 23 amino acids transmembrane domain and either 34 or 302 amino acids cytoplasmic 
domain, via alternative splicing (46, 47). These splice variants have been named as OB-R 
short form or long form transcripts, respectively (47). Transcripts of the two forms are 
identical until the fifth codon 5' of the stop codon of the short form, at which point they 
diverge completely, suggestive of alternative splicing ( 47). 
OB-R is expressed in choroid plexus and several other tissues including 
hypothalamus. Genetic mapping of the gene encoding OB-R shows that it is within the 
5. 1 cM interval of mouse chromosome 4 that contains the db locus (46). 
Human OB-R homologue has a 78 % amino acid sequence homology compared 
with mouse OB-R short form, and encodes 303 amino acid intracellular domain ( 46). The 
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mouse OB-R long form and its human homologue share 71 % identity within their 
intracellular domains (47). 
B. Diabetes mouse (db/db) 
Diabetes (db) is an autosomal recessive mutation located on mouse chromosome 4 
that arose spontaneously in the C57BL/KsJ (BL/Ks) strain (48). Mice homozygous for 
the db mutation are characterized by hyperphagia, early-onset obesity, hyperglycemia, 
hyperinsulinemia, and degenerative changes in the islets of Langerhans, the severity of 
which depends upon the inbred strain on which the mutant allele has been bred ( reviewed 
in ref 41). 
The db mutation results in an obese phenotype similar, if not identical, to that seen 
in ob/ob mice, and db/db mice have been hypothesized to be resistant to ob gene product. 
When an ob/ob mouse is parabiotically joined to its lean littermate the obese mouse 
exhibited normalization of body weight; in contrast, when a db/db mouse is parabiosed to 
a its lean littermate the obese mouse did not exhibit weight loss (49). When an ob/ob 
mouse is parabiosed to a db/db mouse, the body weight of the ob/ob mouse is reduced, 
suggesting the db/db mouse secretes a satiety signal to which it cannot respond but that 
the ob/ob mouse does not produce but can respond to (49). 
High levels of the OB protein are present in plasma from db/db mice. Exogenous 
administration, either peripherally or centrally, of the mouse recombinant OB protein fails 
to reduce body weight and food intake in db/db mice (43). This again suggests that the 
genetic defect in db/db mice renders them unable to appropriately respond to OB protein, 
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perhaps because of a defect in the OB receptor or an postreceptor OB signal transduction 
(43, 44). 
Molecular analysis has revealed that db/db mice have a I 06 nt insertion at the point 
where the long and short forms of OB-R diverge. The insertion sequence includes 
sequence encoding the last five amino acids, stop codon, and the first 88 bp of the 3 '  
untranslated region (UTR) of the short form of OB-R. Further, a genetic point mutation 
(G� T) is detected 2 nt downstream of the I 06 nt insertion at the corresponding region of 
db/db genomic DNA and the transcript then continues as observed for the wild-type long 
form transcript of OB-R ( 4 7). This G� T change creates a new splice donor site, as it is 
very similar to the consensus sequence ( 4 7). Therefore, mutant transcripts of OB-R are 
produced in db/db mice when the common upstream donor site is exclusively spliced to 
the short form acceptor and the new donor is spliced to the long form acceptor. The net 
result is two mRNAs encoding identical OB-R proteins with short intracellular domains 
but with different 3 '  UTR, and fails to encode the mature long intracellular domain. This 
mutation would only affect the intracellular domain of OB-R and thereby radiolabeled OB 
protein binds as well to the choroid plexus of db/db mice as to wild-type mice ( 46). 
This characterization of a mutation in the gene encoding the OB-R protein in 
db/db mice strongly supports the hypothesis that db encodes the leptin receptor. 
Furthermore, genetic mapping and genomic analysis reveals that mouse db and the gene 
encoding the OB-R are the same gene (50). Accordingly, it is predicted that long 
intracellular domain of OB-R is crucial for initiating intracellular signal transduction of 
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regulatory pathway for body fat, and as a corollary, the inability to produce this form of 
OB-R leads to the severe obese phenotype found in db/db mice. 
C. Fatty rat (fa/fa) 
The mutation fatty (fa) first appeared in a cross between Sherman and Merck 
stock M rats and causes juvenile-onset obesity, hyperphasia, hyperlipemia, and 
hyperinsulinemia ( 40, 5 1  ). Hyperglycemia is not generally found in/ atty rats ( 52). 
The/ a gene maps to rat chromosome 5 in a region of conserved synteny with the 
mouse chromosome 4 region containing db, suggesting that/ a and db are mutations in 
homologous genes (53). Comparison of genomic DNA from Zucker/al/a rats and +/+ 
rats on Southern blots probed with mouse OB-R cDNA reveals different hybridiz.ation 
patterns (50). The restriction fragment length variations (RFL V) patterns of the/a/fa 
genomic DNA suggest that the/ a phenotype is the result of a small insertion or deletion in 
the OB-R gene (50). On the basis of mapping data and mutation analysis, it has been 
concluded that db, fa, and Ohr are the same gene (50). However, the precise mechanisms 
by which the mutation produces the apparent loss of function of OB-R remain to be 
defined. 
The obesity of fatty rat appears to be transmitted as an autosomal both codominant 
and recessive trait. An anonymous human DNA probe (VC85) that is tightly linked to the 
fa locus on rat chromosome 5 can detect restriction fragment length polymorphism 
(RFLP) of Zucker and Brown Norway DNA. Therefore, it is possible with the VC85 
probe to genotype segregating fa in the progeny of Zucker and Brown Norway intercross 
(BNZ), although it can not detect the genotype within the Zucker rat strain (54). In F2 
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progeny of Zucker and BNZ F 1-fa/ + intercross, at 7 days of age, both body weight and 
fat pad weight are linearly related to the number of copies off a inherited, suggesting that 
effects of fa on body weight and fat pad weight appear codominant rather than recessive 
at this age (55). At 14 days of age, body weight and fat pad weight clearly increase in the 
animals carrying two copies of fa, but there are without difference between those carrying 
zero copies and those carrying one copy off a, suggesting that the recessive aspects of the 
obese phenotype caused by fa appear by this age (55). 
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III. MOLECULAR CHARACTERISTICS OF THE AGOUTI GENE 
A. The mouse agouti gene and its expression pattern 
The agouti gene in mouse chromosome 2 encodes a I 3 I -amino acid protein 
containing a consensus signal sequence, a highly basic central region, and a cysteine-rich 
carboxyl terminal region (56, 57). The agouti gene has three coding exons that are 
alternatively spliced to two different sets of 5' untranslated exons, resulting in four types 
of mature O. 7- to O. 8-kb transcripts with identical coding regions. One set is expressed 
only in the ventrum; the other set in hair-cycle specific and is expressed only during hair 
growth (56-58). There are two wild-type alleles in the agouti locus, agouti (A) and light­
bellied agouti (Aj ( 60), although recent studies suggest that the A allele may have arisen 
through mutation of Aw, making Aw the true wild-type allele (58, 59). The A mice have 
agouti hairs all over their body resulting from sole expression of the hair-cycle-specific 
transcripts, while the Aw mice have an agouti dorsum with a yellow ventrum resulting from 
a pulse of agouti expression during the hair-growth cycle in the dorsum and continuous 
expression during the hair-growth cycle in the ventrum (58, 59). 
B. Molecular nature of the agouti dominant mutations 
Several studies have shown that yellow obese mice result when the agouti gene is 
ectopically overexpressed (58, 59, 60-65). In fact, the dominant agouti mutations 
including AY and A"" are promoter mutations that result from agouti coding exons being 
placed under the control of ubiquitous promoters. None of the dominant mutations 
identified to date alter the coding region of the agouti gene. 
2 1  
1 .  Lethal yellow (AY) mutation 
Lethal yellow (AY) is a recessive lethal and is associated with a number of dominant 
pleiotropic effects in the heterozygous condition. 
A1/- mice express size-altered agouti mRNA in all adult tissues examined while 
wild-type A/a mice express agouti mRNA only in the skin during the time of phaeomelanin 
synthesis (6 1 ,  62). A'-specific agouti mRNA corresponds to the 5' untranslated region of 
a gene called Raly, a ubiquitously expressed heterogeneous nuclear ribonucleoprotein 
(hnRNP) gene, and entire coding portion of the agouti gene (6 1 ,  62). This chimeric Ralyl 
agouti transcript results from a 170-kb deletion that removes all but the promoter and 
noncoding first exon of Raly, which lies in the same transcriptional orientation as agouti 
and maps 280 kb proximal to the 3' end of the agouti gene (63). A proposed model to 
account for the production of the altered-sized Ra/y/agouti chimeric transcripts that are 
expressed from the A' allele is that transcription initiates at the Raly promoter and 
proceeds through the first Raly exon; however, because the remainder of the gene is 
deleted, transcription proceeds into the remaining intergenic DNA and through the 
downstream exons of the agouti gene. The resulting novel primary transcript could be 
spliced in a manner whereby the splice donor associated with the first exon of Raly 
connects to the available splice acceptors in the downstream exons of the agouti gene, 
resulting in overexpression of agouti coding region in a ubiquitous manner under the 
control of Raly promoter. 
Because Raly has the potential to encode a novel RNA-binding protein that is 
normally expressed in the preimplantation embryo and throughout development, it may 
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have a critical role in development. Accordingly, the embryonic lethality of the 
homozygous A" mutation may result from the lack of Raly gene expression in the early 
embryo. 
2. Viable yellow (A"') mutation 
Unlike A", homozygotes of viable yellow (A"') allele is viable, as the name implies. 
Avyl- mice express agouti mRNA indistinguishable in size in every tissue of the body rather 
than just in the skin and testis. Molecular cloning studies indicate that Avy-specific RNA is 
chimeric containing a foreign 5' sequence with the normal agouti coding sequences (64). 
The foreign 5' sequence in the A vy _ specific RNA does not contain an open reading frame 
with an ATG predicted to initiate translation and is instead derived from an intracisternal 
A particle (IAP) element which is inserted 1 00 kb upstream of agouti coding sequences 
(64). IAP elements are defective retroviruses encoded by a family of endogenous proviral 
sequences present at about 1000 copies per haploid genome in Mus muscu/us ( 66). IAP 
elements are expressed widely during early embryonic development but only in restricted 
tissues in the adult animal ( 66), and transpositions to new places in the genome can 
activate or inactivate the expression of adjacent genes. Factors that control IAP 
transposition are not well understood. The IAP associated with the Avy allele appears to 
activate agouti expression by initiating transcription from a cryptic promoter found within 
the IAP long terminal repeats (L TR) which are met at the termini of the integrated element 
and carry a promoter and enhancer that can act on cellular as well as viral sequences (64, 
65) .  
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The A"' allele is of special interest because the expressivity of the phenotype can 
vary from one to another, even among siblings of a single litter. A"'I- mice exhibit a broad 
spectrum of coat colors that range from solid yellow, to yellow with varying amounts of 
agouti mottling, all the way to a coat color that has been referred to as pseudoagouti, 
which is similar to wild-type agouti pigmentation. Similar to the coat color variations, the 
degree of obesity is also heterogeneous. The expressivity of this mutant phenotype is 
related to the degree of expression of agouti; mice with a solid yellow coat ectopically 
express agouti mRNA at high levels and exhibit marked obesity, whereas pseudoagouti 
mice express agouti mRNA at a very low level and remain lean. 
Although the precise mechanism for the variegated expression is not clear, this 
differential expressivity of the A"' allele appears to be correlated with the methylation 
status of the inserted IAP 5' L TR. This mechanism is deduced from molecular analysis of 
a new dominant agouti allele (A;0") which exhibits very similar genetic and phenotypic 
characteristics as A"' (65). The regulatory region of the IAP 5' LTR in pseudoagouti mice 
carrying A iapy is almost completely methylated, but is hypomethylated in solid yellow mice 
carrying A iapy. Further, it has been known that the expression ofIAP proviral elements is 
inversely correlated with the methylation state of their 5' L TRs (67). 
3. Transgenic mouse assay 
Even though several studies have shown that the action of an ectopic agouti 
protein is responsible for the obesity, diabetes, and other dominant pleiotropic effects in 
the dominant agouti mutant mice, the nature of the structural changes introduced in the 
agouti locus in these mutations, including a 170-kb deletion of 5' flanking DNA and the 
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insertion of retrotransposable elements within the locus, makes it unclear to unequivocally 
conclude that the ubiquitous expression of agouti solely causes the pleiotropic phenotypes 
in these mutations. Transgenic mice in which the expression of a wild-type agouti cDNA 
is under the influence of ubiquitously expressed promoters, such as human 13-actin or 
mouse phosphoglycerate kinase (PGK) promoter, not only express agouti in a ubiquitous 
manner but also develop obesity, hyperinsulinemia, and insulin resistance, as well as 
yellow fur ( 68, 69). The average weight of transgenic mice derived by 13-actin promoter 
and PGK promoter first become significantly greater than the control by about 4-6 weeks 
of age and 8- 14  weeks of age, respectively (68). By 20 weeks of age, transgenic mice 
develop significantly higher level of plasma insulin and only male transgenic mice exhibit 
hyperglycemia ( 68). Moreover, transgenic mice carrying transgene of J3-actin promoter/ 
agouti cDN A containing a point mutation in the agouti coding region do not exhibit 
transgene-induced yellow fur coloration, even though transgene expression has been 
detected at the RNA level in the skin (69). These transgenic models now demonstrate that 
ectopic overexpression per se of the agouti gene is responsible for the phenotypes 
exhibited by mice carrying dominant agouti mutations. 
C. Human homologue of the mouse agouti gene 
The human homologue of the mouse agouti gene has been cloned and mapped to 
human chromosome 20 (70, 7 1 ). The human agouti gene has been shown to influence 
coat color in transgenic mice (7 1 ). Sequence analysis reveals that the coding region of the 
human agouti gene is 85% identical to the mouse gene at the nucleotide level and 800/o 
identical at the amino acid level (70, 7 1  ). Like the mouse protein, the amino terminus of 
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the putative human protein is indicative of the features of a signal peptide (70, 7 1  ). The 
human agouti gene is expressed in adipose tissue, heart, ovary, and testis and to a lesser 
extent in foreskin, kidney, and liver (70, 71). This presence of agouti transcripts in human 
tissues may speculate a role for the agouti gene in skin pigmentation, cardiovascular 
function, energy metabolism, and fertility (72). 
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IV. MODELS FOR AGOUTI ACTION IN PIGMENTATION 
In mammalian pigmentation, tyrosinase is the rate-limiting enzyme involved in 
synthesis of both eumelanin and phaeomelanin. Decreased tyrosinase activity results in 
phaeomelanin synthesis, while high tyrosinase activity results in eumelanin production in 
the melanocyte (reviewed in ref 73). Tyrosinase activity in melanocytes is regulated by cx­
melanocyte stimulating hormone (a-MSH). cx-MSH stimulates melanin formation in 
melanocytes by binding to a membrane receptor and activating adenylate cyclase via a G 
protein-coupled pathway (74). cx-MSH induces an increase in the transcription of the 
tyrosinase gene (75, 76) and activity (77, 78), and thereby induces eumelanin synthesis 
(79, 80). The relative amounts of eumelanin and phaeomelanin in the melanocyte are 
controlled primarily by two loci in mammals, extension which encodes cx-MSH receptor 
(81) and agouti. In contrast to agouti, dominant extension mutation exhibits increased 
eumelanin pigment, resulting in black mice, while recessive mutation blocks eumelanin 
synthesis resulting in yellow mice (82). 
Previous experiments suggested that injection of the a-MSH promoted black 
pigment synthesis after injection into dominant agouti mutants, but not in yellow recessive 
extension mutants, suggesting that agouti is an antagonist of cx-MSH which prevents 
binding or signaling and result in yellow pigment ( 1 ). It has been reported that agouti 
protein is a competitive antagonist of cx-MSH, inhibiting a-MSH binding to its receptor 
and thereby inhibiting cx-MSH-induced cAMP (83). The highly cysteine-rich C-terminal 
domain of agouti protein retains the bioactive characteristic for cx-MSH antagonism (84). 
Therefore, the predominant yellow fur in dominant agouti mutations appears to be through 
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antagonism of the a.-MSH receptor, thereby preventing the elevation of intracellular 
cAMP and eumelanin production. 
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V. OBESITY-DIABETES SYNDROME AND INTRACELLULAR CALCIUM 
A. Insulin resistance in obesity-diabetes syndrome 
Obesity and non-insulin-dependent diabetes mellitus (NIDDM) often coexist and 
are frequently complicated by insulin resistance (85, 86). In the U. S . ,  800/o ofNIDDM 
patients are obese and about 20% of obese individuals are diabetic (87). Insulin resistance 
is defined as a subnonnal biologic response to a given concentration of insulin. Although 
insulin's effects are pleiotropic, the term "insulin resistance" typically refers to the actions 
of insulin on glucose homeostasis. Obesity and NIDDM is also characterized by 
hyperinsulinemia, secondary to insulin resistance (88). Although fasting insulin levels do 
not directly measure insulin resistance, there is evidence that the rank order of basal and 
stimulated insulin levels correlate highly with the reciprocal of tissue insulin sensitivity 
(89). In addition, several epidemiological studies have found higher basal insulin levels 
and reduced tissue insulin sensitivity in obese subjects compared with lean subjects (90-
92). 
B. Insulin signaling 
In mammals, insulin is the principal hormone controlling blood glucose and acts by 
stimulating glucose influx and metabolism in muscle and adipocytes, and inhibiting 
gluconeogenesis by the liver. In addition, insulin modifies the expression or activity of a 
variety of enzymes and transport systems in nearly all cells. Insulin's diverse actions are 
initiated by interaction with a specific receptor, a transmembrane glycoprotein with 
intrinsic protein tyrosine kinase activity. 
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The insulin receptor is present in virtually all vertebrate tissues, although the 
concentration varies from as few as 40 receptors on circulating erythrocytes to more than 
200,000 receptors on adipocytes and hepatocytes (93). The human insulin receptor gene 
is located on the short arm of human chromosome 19, is more than 150 kb in length and 
contains 22 exons which encode a 4.2-kb cDNA (94). The insulin receptor is composed 
of two a-subunits that are each linked to two J3-subunits and to each other by disulfide 
bonds . Both subunits are derived from a single proreceptor by proteolytic processing at a 
cleavage site consisting of four basic amino acids. There is one site of alternative splicing 
surrounding exon 11, which results in two receptor isoforms differing by 12 amino acids 
near the COOH terminus of the a-subunit. In the mature heterotetramer ( a2J32) receptor, 
the a-subunits are located entirely outside of the cell and contain the insulin binding 
site( s ), whereas the J3-subunits span the plasma membrane and the intracellular portion of 
the J3-subunits contain the insulin-regulated tyrosine protein kinase. After insulin binding, 
specific tyrosine residues of the J3-subunits are rapidly phosphorylated, and the tyrosine 
kinase intrinsic to this region is activated (95, 96). The immediate consequences of the 
activation of the tyrosine kinase activity of the insulin receptor remain poorly defined. 
In addition to signal transduction, the insulin receptor mediates internalization of 
insulin. Endocytosis of the insulin-receptor complex leads to insulin degradation, while 
most of the unoccupied receptors recycle to the plasma membrane. After prolonged 
insulin stimulation, the receptor itself is degraded, resulting in receptor down-regulation 
and attenuation of the insulin signal (97, 98). Dephosphorylation of the insulin receptor by 
tyrosine phosphatases is one likely mechanism for termination of the signal (99). 
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However, the identity and regulation of specific phosphatases that act on the insulin 
receptor are not known. Substantial evidence points to a role of serine/threonine 
phosphorylation of the insulin receptor in inhibitory regulation of insulin signaling. 
Several serine/ threonine residues have been identified , in C-terminal and juxtamembrane 
regions of the insulin receptor, which become phosphorylated in response to activation of 
protein kinase C or the action of insulin itself ( 100, 101 ). 
C. A potential network of insulin signaling pathways mediated through activation of the 
insulin receptor kinase and phosphorylation of IRS- I or She 
Despite an explosion of information concerning intermediates of intracellular 
signaling pathways utilized by receptor tyrosine kinases, understanding of the mechanism 
of cellular insulin action remains poor. The proteins classically regulated by insulin ( e.g. 
glycogen synthase and glucose transporters) are not functionally activated by tyrosyl 
phosphorylation, while many cellular actions of insulin are regulated by phosphorylation or 
dephosphorylation of serine/threonine residues. 
Accordingly, one hypothesis is that insulin action involves a phosphorylation 
cascade, with the receptor at one end and enzymes that undergo increased or decrease 
serine/threonine phosphorylation at the other. In this hypothesis, the first intermediate in 
the signal transduction pathway must be a protein phosphorylated on tyrosine. With using 
anti-phosphotyrosine antibodies, insulin receptor substrate- I (IRS- I) was initially detected 
in insulin-stimulated Fao hepatoma cells, and originally termed pp 185 based on its 
migration during SOS-PAGE (102). IRS- I is widely distributed in tissues and contains 21 
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potential tyrosine phosphorylation sites. At least 8 tyrosines in IRS-I undergo 
phosphorylation by the activated insulin receptor (93, I 03). 
To propagate the signal, IRS-I binds several proteins containing Src homology 2 
domains (SH2 proteins) through its multiple tyrosine phosphorylation sites. The SH2 
proteins associated with IRS- I include phosphatidylinositol (PI) 3 '-kinase, SH-PTP2 
(Syp ), a protein tyrosine phosphatase, and GRB-2, a small cytoplasmic protein that acts as 
adapter molecule linking the guanine nucleotide exchange factor for p21 ,as, termed mSOS 
(homologous to the Drosophila protein, son-of-sevenless (Sos)) to tyrosyl 
phosphoproteins (103). The binding of GBR-2/mSOS to IRS-I may mediate the insulin 
stimulation of p21 ,as. However, Ras is also stimulated by insulin through insulin­
stimulated tyrosine phosphorylation of She ( 104) or the direct binding of p21 ,as to the 
insulin receptor ( 105). Ras has been shown to bind directly Raf- I serine/threonine kinase, 
which in tum activates MAP (microtubule-associated protein) kinase by phosphorylation 
and activation of the MAP kinase kinase (106). 
There is an evidence that PI 3 '-kinase plays an essential role in insulin signaling to 
glucose transport, glycogen synthesis and inhibition of lipolysis. In particular, specific 
inhibitors of PI 3 '-kinase block the effects of insulin on these processes ( I 07- 109). 
Insulin appears to stimulate p90nk through the MAP kinase cascade and thereby 
phosphorylate and activate the glycogen-associated protein phosphatase- I ,  which places 
stimulation of glycogen synthase (93). MAP kinase may play a role in effects of insulin on 
gene transcription, but not a major pathway regulating insulin-stimulated glucose transport 
and glucose transport-4 translocation (110). 
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The importance of IRS-I in insulin signaling was confinned by use of antisense, 
transfection and microinjection strategies (111-113). However, transgenic mice which 
lack IRS- I ,  as a result of targeted gene disruption, display a phenotype much less severe 
than would be expected if IRS- I were essential for all aspects of signaling by insulin ( 114, 
115). These mice are modestly insulin resistant and growth-retarded, but otherwise 
survive remarkably well. Thus it appears that, although IRS-I plays an important role in 
insulin signaling, there must be alternative mechanisms for activating pathways essential to 
insulin's effects on cell growth and metabolism. 
Most recently, it has been proposed that there exists another member of the IRS-I 
family, p l90/IRS-2, which plays a role similar to IRS- I (115, 116). As PI 3 '-kinase, MAP 
kinase, and Syp have been implicated in mediation of diverse responses to many different 
growth factors and cytokines (117-119), it is therefore probable that an insulin-specific 
step may exist and defects in this step may be related with insulin resistance at post­
receptor events . 
D. Intracellular calcium in insulin action and insulin resistance 
The roles of intracellular calcium ([Ca2+]i) in insulin action has been previously 
proposed by several studies (reviewed in ref 118), although not all studies support this 
concept. For instance, Klip et al. (121) and Kelly et al. (122) failed to show involvement 
of [Ca1+]i in insulin action on muscle cells and adipocytes. 
Ca1+ involvement in insulin action may be expressed at various levels of cellular 
metabolism. The insulin receptor contains a high-affinity Ca1+ -binding site and its 
phosphorylation is Ca2+-dependent (123). It also has a calmodulin domain (124). In the 
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adipocyte plasma membrane, insulin increases both Ca2+ binding ( 125) and the high­
affinity binding sites for calmodulin, and via its receptor kinase, it also stimulates 
calmodulin phosphorylation ( 126- 128). In tum, calmodulin enhances insulin-evoked 
phosphorylation of the insulin receptor �-subunit ( 127). 
Glucose transport in adipocytes is Ca1+-dependent ( 129, 130) and so is liver 
glucose-6-phosphatase activity ( 13 1). Insulin has been found capable of increasing [Ca1+]i 
in adipocytes ( 132, 133), possibly indicating Ca1+ as a signal for insulin-mediated 
processes. Draznin et al. ( 133) have proposed that insulin-mediated glucose transport is 
maximized only within an optimal range of [Ca2+]i, and those elevations of basal [Ca2+]i 
beyond this range can cause insulin resistance. Furthermore, they have suggested that 
insulin resistance in obese and NIDDM patients results from high basal [Ca2+]i in 
adipocytes, and showed that it can be reversed in vitro by treatment with the Ca1+ -channel 
blocker verapamil ( 133). In support of this concept, Byyny et al. ( 134) found that calcium 
channel blockade with nitrendipine in obese-elderly-hypertensive-patients resulted in 
significant increases in insulin-stimulated 2-deoxyglucose uptake in adipocytes obtained 
from abdominal wall biopsies. In contrast, Kelly et al. ( 122) could not demonstrate a 
relation between a rise in [Ca2+]i in adipocytes and insulin resistance; however, they did 
observe a strong correlation between Ca2+ influx and inhibition of insulin-dependent 
glucose transport. Therefore, although further research is needed to establish the 
mechanisms by which [Ca1+]i produces insulin resistance, the evidence indicates that 
abnormal cellular calcium handling, particularly sustained elevation in [Ca1+]i may be 
involved in insulin resistance. This, in tum, may be due to a diminished ability of insulin to 
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appropriately modulate [Ca2+]i in cells with pre-existing elevations. Although the 
mechanisms that lead to such increases are not yet well understood, they appear to include 
an enhanced influx of calcium via calcium channels. 
E. Effects of calcium channel blockade on insulin resistance and obesity 
A large body of evidences has demonstrated an improvement of insulin sensitivity 
by calcium channel blockers. Voltage-dependent, L-type, calcium channel complexes 
contain at least three distinct binding sites : the dihydropyridine site, at which drugs such as 
nitrendipine, nifedipine, nimodipine and isradipine bind, the penylalkylarnine site at which 
drugs such as verapamil and flunarizine act, and the benzothazepine site at which diltiazem 
binds (135, 136). The phenylalkylamine and benzothazepine binding sites are allosterically 
linked to the dihydropyridine site. Diltiazem increases the binding of dihydropyridines at 
their receptor sites and dihydropyridine calcium channel antagonists allosterically increase 
diltiazem binding, while veraparnil showed complex biphasic inhibition of dihydropyridine 
binding (136-139). 
1. Animal studies 
Treatment with nitrendipine for 3 weeks decreased fasting glucose level and 
significantly improved glucose tolerance in non-obese spontaneously hypertensive rats 
without a change of body weight ( 140). This improved glucose tolerance appeared to be 
due to an increase in glucose uptake in muscle ( 140). 
Benidipine, a dihydropyridine calcium antagonist, decreased body weight and body 
fat in mice made obese by pretreatment with monosodium-L-glutamate (MSG) ( 141 ). 
Benidipine appears to activate brown adipose tissue to induce body weight loss ( 141 ). 
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Nifedipine treatment for one month significantly decreased body weight compared 
to controls and three month treatment resulted in decrease in total, abdominal, and 
subcutaneous fat masses in nine-month-old obese female and male SHHF /Mcc:fa"P rats 
(142). Nifedipine also reduced plasma triglyceride and fasting glucose levels and 
improved in insulin response to an oral glucose load in obese females but was without 
effects in obese males of SHHF/Mcc:fa"P rats (142). 
2. Clinical studies 
Two different types of calcium channel antagonist, nitrendipine and diltiazem 
improved glucose tolerance, lowered fasting and glucose-stimulated circulating insulin 
levels in insulin-resistant obese and hypertensive patients (143, 144). Obese hypertensive 
elderly patients demonstrated marked hyperinsulinemia and reduced submaximally 
stimulated 2-deoxyglucose (DG) uptake in adipocytes which exhibited an elevated [Ca2+]i 
(134). One month of therapy with nitrendipine reduced plasma insulin to control values 
during an oral glucose tolerance test in obese hypertensive individuals and restored 2-DG 
uptake at submaximally effective insulin concentrations to control values in normal weight 
and obese hypertensive subjects (134). Similarly, the long-acting Ca
2+ -channel blocker 
amlodipine reduced steady-state plasma glucose and improved insulin sensitivity in 
essential hypertensive subjects (145). Further, verapamil normalized metabolic 
derangements, including glucose uptake, glycogen synthase and glycogen content, in 
hemodialysis patients who were characterized by increased basal [Ca2+]i in 
polymorphonuclear leukocytes ( 146). 
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F. Mechanisms by which increased intracellular calcium produces insulin resistance 
1 .  Attenuation of dephosphorylation and activation of insulin-sensitive substrates including 
glucose transporter-4 and glycogen synthase 
The molecular mechanism(s) by which increased [Ca21i induces insulin resistance 
is poorly understood, but a number of potential candidate steps at which metabolic control 
of glucose disposal may occur can be identified. These include any of the rate-limiting 
steps in glucose metabolism, such as ( 1 )  insulin receptor binding ( and subsequent kinase 
activity), (2) glucose transport across the cell membrane, (3) glucose oxidation, and (4) 
glycogen synthesis. The effects of [Ca2+]i on insulin binding and insulin receptor kinase 
activity have been addressed in studies using adipocytes with normal and elevated [ Ca2+]i 
( 147). The results of these studies do not distinguish any unambiguous change in insulin 
binding or tyrosine kinase activity of the insulin receptor in cells with high levels of 
cytosolic calcium ( 14 7). 
Several investigators have demonstrated impaired stimulation of the glucose 
transport system in adipocytes and muscle strips of obese individuals and NIDDM patients 
( 148- 1 50). The transport of glucose across animal cell membranes is catalyzed by 
members of two distinct gene families ( 15 1 ). The facilitated-diffusion glucose transporters 
are ubiquitously expressed in mammalian cells ( 152), whereas the Na+/glucose 
cotransporters appear to be restricted to selected epithelial cells of renal tubules and the 
intestinal mucosa ( 1 53). The Na+-dependent proteins are secondary active-transport 
systems that reside in the apical membranes of the epithelia and concentrate glucose from 
the intestinal contents and the forming urine. The facilitated-diffusion transporters are 
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passive systems that equilibrate sugar across membranes. The latter proteins are 
responsible for the movement of sugar from the blood into cells, supplying cellular glucose 
for energy metabolism and the biosynthesis of sugar-containing macromolecules. 
Glucose transport by facilitated diffusion is mediated by a family of tissue-specific 
membrane glycoproteins. To date, six genes encoding homologous but distinct glucose 
transporter (GLUT} proteins, and one pseudogene that does not encode protein, have 
been identified and designated GLUT l -7, based on the order in which they were cloned 
( 1 54, 1 55). These glucose transporter proteins are highly homologous integral membrane 
proteins with 12  membrane-spanning domains, a single glycosylation site, and cytoplasmic 
NH2 and COOH termini. 
GLUT 4 is the insulin-responsive transporter isoform and is expressed exclusively 
in tissues that exhibit acute activation of glucose uptake by insulin, mainly adipose and 
skeletal muscle tissues ( 1 56). GLUT 4 protein levels were reported to be depressed by 23 
% in the obese nondiabetic and 1 8  % in the obese NIDDM individuals ( 1 57). However, 
Pederson et al. ( 1 58) and Handberg et al. ( 1 59) found that GLUT 4 levels are normal in 
vastus lateralis biopsied from NIDDM patients. Nonetheless, insulin stimulates a 
translocation of GLUT 4 from an intracellular membrane pool to the plasma membrane 
and increases the intrinsic activity of the GLUT 4 ( 1 60). The intrinsic activity of GLUT 4 
depends on the phosphorylation state ( 161  ). Phosphorylation of serine residues ( 16 1 )  on 
GLUT 4 significantly diminishes its intrinsic activity ( 1 62). Insulin promotes 
dephosphorylation of GLUT 4 ( 163) through phosphoserine phosphatase 1 (PPl}  which is 
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activated by an insulin-stimulated protein kinase (161). Further, okadaic acid, an inhibitor 
of phosphatase I and 2A, inhibits the insulin-stimulated glucose transport (164). 
The phosphorylation status of GLUT 4 was significantly increased in adipocytes 
when cells were depolarized with K+ or exposured to parathyroid honnone (PTH), both of 
which cause an increase in Ca2+ influx, while nifedipine reduced GLUT 4 phosphorylation 
toward control levels in K+-treated cells (165). Similarly, a combination of a cAMP 
antagonist (RpcAMP) and nitrendipine restored GLUT 4 phosphorylation in PTH treated 
cells (165). 
PP 1 is a ubiquitous enzyme that exists in association with glycogen particles, 
myosin, or other subcellular components (I 66). So far, glycogen-associated PP 1 has been 
studied most extensively and has been found to contain a regulatory, or glycogen-bound, 
subunit (G-subunit) and a catalytic subunit (C-subunit) (167). The regulatory G-subunit 
contains two serine phosphorylation sites ('site- I '  and 'site-2'). When dephosphorylated 
the G-subunit binds the C-subunit, producing a less active protein. An insulin-stimulated 
protein kinase (ISPK-1) promotes phosphorylation of ' site- I ' of the G-subunit, turning 
PPI into a 'more active' state. In contrast, cAMP-dependent kinase (PKA) mediates full 
phosphorylation of both 'site- I '  and ' site-2' of the G-subunit. PKA also phosphorylates 
and activates the specific inhibitor of PPl (Inhibitor- I )  and allows the inhibitor to bind to 
the C-subunit of PP l (168-170). Accordingly the C-subunit of PPI dissociates from the 
G-subunit and becomes inhibited. Three structurally similar, but genetically distinct 
isofonns of PP l catalytic subunit (PP la, PP1J3, and PPly) were identified in different 
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mammalian tissues including skeletal muscle ( 171-17 4) and PP 1 J3 appeared to be the 
predominant glycogen-bound from in rabbit skeletal muscle (175). 
Reduced basal and insulin-stimulated activity of PP 1 was shown in skeletal muscle 
of insulin-resistant Pima Indians ( 176). Sustained elevations of [Ca2+]i induced by K+ or 
PTH were also accompanied by inhibition of PP 1 activity in insulin target cells ( 170, 
177). However, which classes of PP I are inhibited by high [Ca2+]i remains unknown. 
This inactivation of PP 1 mediated by high [Ca2+]i is, in part, due to 
phosphorylation and activation of inhibitor- I ( 170). Phosphorylation of inhibitor- I 
significantly increases in cells with elevated [Ca2+]i, while calcium channel blockade with 
nitrendipine completely prevents increases in inhibitor- I phosphorylation ( 170). 
Impaired insulin-stimulated nonoxidative glucose metabolism is a frequent finding 
in patients with overt NIDDM ( 178), predominantly due to an impairment in glycogen 
synthesis rate in skeletal muscle (179). The first event in the biogenesis of glycogen in 
skeletal muscle is catalyzed by a protein tyrosine glycosyltransferase and involves the 
covalent attachment of glucose to a single tyrosine residue at position 194 on the priming 
protein, termed glycogenin ( 180- 186). The nature of the tyrosine glucosyltransferase is, 
however, not known and it is also unknown whether this first step in glycogen formation is 
under hormonal control. Once the first glucose is attached to the glycogenin backbone the 
glucan chain from the tyrosine 194 residue is extended by sequential addition of up to 
seven further glucose residues. This process is mediated by glycogenin itself (Mn2+ /Mg2+ -
dependent autoglycosylation). Glycogen synthase (GS) is then able to elongate the glucan 
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chain, but only when glycogenin and GS are complexed together. Moreover, it appears 
that GS dissociates from glycogenin during the later stages of glycogen biogenesis. 
Glycogen formation and breakdown are controlled by GS and glycogen 
phosphorylase, respectively. Both enzymes are regulated covalently by 
phosphorylation/dephosphorylation. GS catalyzes the rate-determining reaction of 
glycogen synthesis, i.e., the transfer of glycosyl units from UDP-glucose to the glycogen 
molecule: 
UDP-glucose + glycoge11n � UDP + glycogell(n+ I> 
GS 
GS can exist as a dephosphorylated form of high activity or as less active phosphorylated 
form which is stimulated by glucose-6-phosphate (G-6-P), a well-known allosteric 
activator ( 1 87). In diabetic subjects, a defect in dephosphorylation (insulin resistance) 
may be compensated for by an increase in intracellular G-6-P. Dephosphorylation of GS is 
regulated by the serine phosphatase, PPl (188). 
Depolarizing rat adipocytes increased [Ca2+]i and subsequently reduced PPl 
activity and the dephosphorylation of GS accompanied ( 1 89). Calcium channel blockade 
with nitrendipine or incubation with Ca2+ free medium completely restored 
dephosphorylation of GS, suggesting dephosphorylation of GS is regulated by [Ca2+]i 
( 1 89). 
Accordingly, high [Ca2+]i may induce insulin resistance by inhibiting the 
dephosphorylation of GLUT 4, glycogen synthase and other insulin-sensitive substrates. 
4 1  
2. Negative feedback induced by protein kinase C 
A substantial body of observations indicates that protein kinase C (PKC) plays a 
role in the insulin-evoked cellular response ( 190- 192). Insulin increases di3cylglycerol 
(DAG) and stimulates PKC activity in myocytes and adipocytes through the translocation 
of the enzyme to the plasma membrane and by an increase in its reaction velocity (1 90). 
Phobol esters, which stimulate PKC by binding to the DAG site of PKC, mimic insulin's 
effect on stimulation of 3-0-methylglucose (3-0MG) uptake in rat fat cells by stimulating 
phosphorylation of the J3-subunit of the insulin receptor (1 93). Inhibitors of PKC blunt 
insulin-induced 2-DG uptake in rat adipocytes, while agonist of PKC directly stimulates 
glucose transport in BCJH- 1 myocytes ( 191) . 
PKC also appears to play a role in regulatory feedback of insulin action by 
inhibiting the binding of insulin to its binding sites ( 1 94 ), the phosphorylation of the insulin 
receptors ( 195, 196), and the insulin-evoked stimulation of phospholipase C ( 197). 
Insulin resistance could arise when PKC is stimulated by insulin-independent 
pathways, which in tum would blunt the response to insulin ( 198). Ca2+ is a key factor in 
the PKC translocation from the cytosol to the plasma membrane, "priming" PKC for 
interaction with DAG to assume the PKC active mode (199). Therefore, a rise in DAG 
and [Ca2+]i levels, singly or in combination, could enhance PKC activity through its 
translocation to the plasma membrane (200). Glucose can also stimulate PKC through a 
de novo synthesis of DAG, thereby promoting insulin resistance, and it can be reversed by 
PKC inhibition (201 ,  202). 
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To date, at least ten PKC isozymes have been identified but the physiologically 
important protein substrates have not yet been clearly identified (203). lsozymes of a, b 
and g (cPKCs) are Ca2+-dependent and activated by Ca2+ (204). Therefore cPKC may be 
related to high [ Ca2+]i-mediated insulin resistance which is associated with insulin receptor 
J3-subunit tyrosine kinase inactivation via phosphorylation. 
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VI. THE ANIMAL FATTY ACID SYNTHASE 
Fatty acid synthase (FAS) is a rate limiting enzyme in the long term regulation of 
de novo lipogenesis (205), and its hyperactivity and overexpression is a key feature of 
obese rats (206, 207). Even in advance of the onset ofhyperphagia and hyperinsulinemia, 
FAS is already increased by 50 % in preobese pup adipose tissue in Zucker obese rats 
(208), suggesting FAS as an appropriate obesity marker. 
A. One gene, one pol;mq,tide, seven enzymes 
FAS is a multifunctional enzyme that catalyzes all the reactions in the conversion 
of acetyl CoA and malonyl CoA to long chain fatty acids. The synthesis of fatty acids de 
novo is achieved by the sequential condensation of two-carbon units derived initially from 
acetyl-CoA. The overall reaction sequence can be summarized by: 
Acetyl-CoA + 7 Malonyl-CoA + 14 NADPH + 14 Jr -+  
Palmitic Acid + 7 CO2 + 8 CoA + 14  NADP+ + 6 H20 
The pathway can be described as a cyclic process in which an acetyl primer undergoes a 
series of decarboxylative condensations with seven malonyl moieties; each condensation 
reaction generates a 3-ketoacyl moiety that undergoes the same three-step 13-carbon 
reduction to give a fully saturated acyl moiety two carbon atoms longer than in the 
previous cycle. Thus, after completion of seven cycles of elongation and reduction, the 
final product is the saturated C16 fatty acid, palmitic acid (209). 
FAS comprises two multifunctional polypeptide chains with a subunit M, 250,000, 
each containing seven discrete functional domains, including ketoacyl synthase, 
malonyVacetyl transferase, dehydrase, enoylreductase, ketoreductase, acyl carrier protein 
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(ACP), and thioesterase; these are juxtaposed head-to-tail such that two separate centers 
for fatty acid assembly are formed at the subunit interface (209). 
For initiation of fatty acid synthesis, an acetyl and a malonyl moiety are 
translocated from their CoA thioesters to specific thiol sites on the FAS through 
malonyVacetyl transferase domain of FAS: the acetyl moiety to the ketoacyl synthase and 
the malonyl moiety to the ACP domain. Condensation of acetyl and malonyl moieties is 
accompanied by the loss of C-3 (as CO2) and then the resulting four-carbon acyl moiety 
undergoes reduction, dehydration, and final reduction- catalyzed by three discrete enzyme 
components of the FAS, the ketoreductase, dehydrase, and enoyl reductase, forming a 
saturated acyl moiety. In preparation for the next cycle of elongation, the saturated acyl 
moiety is then transferred back to the ketoacyl synthase and the cycle of condensation, 
ketoreduction, dehydration, and enol reduction is repeated with another malonyl moiety. 
The final palmitoyl moiety is then released as a free fatty acid through the action of the 
resident thioesterase off AS. 
The cDNA sequences encoding the rat (2 1 0-2 1 3), goose (2 1 4), chicken (2 1 5, 
2 16), mouse (2 1 7), and human (2 1 8) F ASs have been reported, and the human FAS gene 
has been mapped to chromosome l 7q25 (2 1 8). 
B. Regulation of fatty acid synthase concentration by nutrients and hormone 
FAS concentration has been known very sensitive to nutritional and hormonal 
status, although the enzyme activity is not regulated by any allosteric effectors or covalent 
modification (205, 2 19). 
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Dietary regulation of FAS concentration is mediated primarily by controlling 
transcriptional activity of the gene. Starvation causes comparable decreases in the 
synthesis rate, mRNA abundance, and transcriptional rate of hepatic FAS in rodents and 
geese; feeding a high-carbohydrate diet reverses these effects (220-229). Dietary 
polyunsaturated fatty acids are potent inhibitors for transcription of hepatic FAS in rats 
(230-232). 
It has been known that an increase in plasma insulin level is directly related to 
increased FAS activity in the liver of rat pups reared on formula rich in carbohydrate 
(233). Streptozotocin-induced diabetic rats exhibit a decreased hepatic FAS synthesis 
rate, which restored with insulin (234). Glucagon or dibutyryl cAMP decreases in the 
synthesis of FAS; the effects of insulin and glucagon on the synthesis of FAS in vivo are 
associated with similar changes in the abundance of FAS mRNA (226, 227). Regulation 
of the level of FAS mRNA by these hormones is largely mediated by alterations in gene 
transcription, and the effect of insulin on the FAS mRNA level is abolished by 
cycloheximide administration, suggesting that ongoing protein synthesis is required for the 
transcriptional activation of the FAS gene by insulin (228). The cis-acting insulin­
responsive element has been found within 70 bp of the transcription start site (235). 
Thyroid hormone (3,5,3'-Triiodothyronine, T3) affects FAS mRNA levels in a 
tissue specific manner; FAS mRNA levels are higher in hyper- than hypothyroid liver of 
rats and in white adipose tissue mRNA expression is increased by hyperthyroidism, while 
in brown adipose tissue, highest levels are recorded in hypothyroid animals (236). 
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Nutritional and honnonal regulations of FAS are also observed in cultured or 
primary adipocytes or hepatocytes. In fully differentiated 3T3-Ll adipocytes, the mRNA 
expression of FAS is stimulated by insulin and T3 and inhibited by dibutyryl cAMP (227, 
23 7). The stimulatory effect of T 3 on FAS mRNA abundance is due to an increase in 
transcription of the gene (23 7). In primary cultures of hepatocytes from adult mouse or 
rat, insulin and T3 enhance and glucagon inhibits the synthesis rate of FAS (238, 239). T3 
causes comparable increases in mRNA abundance and transcription of the FAS gene, 
indicating that primary regulation is transcriptional and requires on-going protein synthesis 
and protein phosphorylation, as inhibitors of protein synthesis or phosphorylation block 
the T3 stimulation effect on FAS transcription (240-242). 
In primary cultured rat adipocytes, glucose causes a five- to seven-fold increase in 
FAS mRNA (243). In contrast, 3-0-methylglucose, a glucose analogue that is transported 
into the cell but not metabolized, was without effect on FAS mRNA levels; however, 2-
deoxyglucose, a glucose analogue that is phosphorylated to 2-deoxyglucose-6-phosphate, 
stimulates the expression of FAS mRNA. This suggests that glucose-6-phosphate or a 
product derived therefrom is involved in mediating the glucose-induced stimulation of 
FAS mRNA in adipose tissue (243). The glucose-induced increase in FAS mRNA in Hep 
G2 cells is due to changes in the stability ofmRNA (244). 
Fatty acids, including octanoate (C8 :0) and hexanoate (C6:0), inhibit the T3-
induced stimulation of transcription of the FAS gene in chick embryo hepatocytes in 
culture (245). Arachidonate (C20:4) inhibits the stimulation of FAS mRNA level caused 
by a combination of insulin, dexamethasone, and T 3 in cultured rat hepatocytes (246). 
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Transcription appears to be the regulated step, as dietary arachidonate inhibits 
transcription of the FAS gene in livers of intact rats (230). 
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PART 3 
EXPERIMENTAL INVESTIGATIONS 
7 1  
I. AGOUTI REGULATION OF INTRACELLULAR CALCIUM: ROLE IN THE 
INSULIN RESISTANCE OF VIABLE YELLOW MICE1 
A. Abstract 
Several dominant mutations at the agouti locus in the mouse cause a syndrome of 
marked obesity, hyperinsulinemia and insulin resistance. Although it is known that the 
agouti gene is expressed in an ectopic manner in these mutants, the precise mechanism by 
which the agouti gene product mediates these effects is unclear. Since intracellular 
calcium ([Ca2+]i) is believed to play a role in mediating insulin action and dysregulation of 
calcium flux is observed in diabetic animals and humans, we examined the status of [Ca2+]i 
in mice carrying the dominant agouti allele, viable yellow (A"'). We show here that in 
mice carrying this mutation, [Ca2+]i levels are elevated in skeletal muscle and the degree of 
elevation is closely correlated with the degree to which the mutant traits are expressed in 
individual animals. Moreover, we demonstrate that the agouti gene product is capable of 
inducing elevated [Ca2+]i levels in cultured and freshly isolated skeletal myocytes from 
wild-type mice. Based on these findings, we present a model in which we propose that the 
agouti polypeptide promotes insulin resistance in mutant animals through its ability to 
increase [Ca2+]i. 
1This manuscript has been published in similar form with co-authors Zemel, M. B. ,  
Woychik, R.  P., Michaud, E.  J., Kadwell, S. H. ,  Patel, I .  R. , and Wilkison, W. 0. 
in: Proc. Natl . Acad. Sci. USA 1 995; 92 : 4733-4737. 
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B. Introduction 
The mouse agouti gene is normally involved in regulating the production of 
pigment granules that give rise to the wild-type coat color, which consists of black hairs 
with a subapical band of yellow ( 1 ,  2). Several dominant mutations at agouti, most 
notably lethal yellow (A') and viable yellow (A"), cause mice to develop a predominantly 
yellow coat color and to become obese, insulin resistant and hyperinsulinemic with age 
(reviewed in 3, 4). These mutants are collectively often called "yellow obese" mutants. 
The agouti gene has been cloned and shown to encode a 1 3 1  amino acid protein 
with a consensus signal peptide ( 5, 6) . Agouti is normally expressed in the skin during 
hair growth (5). Bultman et al. (5) discussed a model for the function of the agouti 
protein that was recently validated at the molecular level (7). Agouti functions in a 
paracrine manner to regulate the differential production of melanin pigments by the 
melanocyte ( 1 ,  2). Normally, a-melanocyte stimulating hormone ( a-MSH) binds to its 
receptor on the melanocyte, activates adenylate cyclase, and thereby causes an increase in 
intracellular cAMP levels which stimulates production of eumelanin (black pigment) (8). 
However, when agouti is present within the hair follicle, it appears to block the ability of 
a-MSH to activate its receptor, thereby inhibiting cAMP production and causing a shift 
from eumelanin to phaeomelanin (yellow pigment) production (7). 
While it is becoming increasingly clear how the agouti protein functions in the hair 
follicle, much less is known about how the agouti gene causes obesity and insulin 
resistance in the yellow mutants. Molecular analysis of A>' (5, 9, 10), Avy ( 1 1 ), and a new 
dominant allele of agouti called A iapy ( 12), revealed that in all cases, the agouti gene, 
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which is normally expressed in the developing hair follicle, has been modified in a manner 
that causes it to be expressed in most, if not all, tissues of the animal. Although agouti is 
being expressed with an altered tissue distribution, it appears to have retained the ability to 
produce a normal agouti protein. Agouti is a secreted molecule; however, agouti appears 
to function in a localized manner (2). Accordingly, the site of synthesis of the agouti 
protein is an important factor to consider in evaluating its biological activity in the animal . 
In this regard, it is presently unclear if it is the ubiquitous expression of agouti per se, or 
perhaps the ectopic expression of agouti in a specific tissue that is directly responsible for 
the development of obesity and the other dominant pleiotropic effects. 
Because the yellow obese mutants are hyperinsulinemic and insulin resistant, and 
because type I muscle fibers (e.g., soleus muscle) are a primary target for insulin action, 
we considered the possibility that the muscle is responsive to the action of the agouti 
protein in yellow obese mutants. There are multiple potential cellular sites of insulin 
resistance; one such site is dysfunctional regulation of [Ca2+]i. Elevations in [Ca2+]i have 
been shown to result in insulin resistance in several systems ( 1 3- 19), although the 
relationship between [Ca2+]i and insulin signal transduction is complex and poorly 
understood. Accordingly, we initiated a series of experiments to measure [Ca2+]i levels 
and transport in insulin-sensitive tissue ( skeletal muscle) of mice carrying the A"' allele of 
agouti, and to determine the role of the agouti protein in regulating [ Ca2+]i. We report 
herein that adult A"'la mice (where a refers to non-agouti) exhibit increases in soleus Ca2+ 
influx and [Ca2+]i that correlate well with the degree of obesity in the animals. We further 
demonstrate that conditioned medium containing recombinant agouti protein stimulates 
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significant increases in [Ca2+]i over the baseline in both freshly isolated and cultured 
skeletal myocytes. 
C. Materials and Methods 
Animals: C57BU6J-A"' mice were purchased from the Jackson Laboratory (Bar 
Harbor, :ME) and maintained at the Oak Ridge National Laboratory (Oak Ridge, TN) by 
mating A"'la mice to ala siblings. Experiments were conducted on three to five-month old 
male and female viable yellow (A"' la) mice exhibiting either pseudoagouti, mottled, or 
yellow coat colors ( see results) and were compared with age-matched non-agouti black 
(ala) mice. 
Preparation of isolated skeletal myocytes: Isolated soleus and gastrocnemius 
myocytes were prepared essentially as described by Beam et al. (20). Briefly, tissue was 
isolated from animals following an overnight fast and gently teased apart along the 
longitudinal axis. The tissue was then incubated at 37  °C for 40 min in a HEPES-buffered 
salt solution (HBSS; composition in mM: NaCl, 1 38; CaCh, 1 . 8; MgS04, 0.8; NaH2P04, 
0.9; NaHC03, 4; glucose, 2S; glutamine, 6; HEPES, 20; and 0. 5 % bovine serum albumin 
(BSA)) containing collagenase (type I, 2 mg/mL). After filtration and centrifugation, the 
cell pellets were resuspended in HBSS for measurement of [Ca2+]i. 
Preparation of cultured L6 myocytes: L6 skeletal myocytes were purchased from 
American Type Culture Collection (ATCC, Rockville, MD) in passage 4. Cells ( 1 . 8 x 106) 
were plated in a 1 50 cm2 flask containing Dulbecco's Modified Eagle's Medium (D:MEM) 
supplemented with S % calf serum, S % fetal bovine serum, 50 U/mL penicillin, 5 µg/mL 
streptomycin and 10 % glucose and maintained in a 5 % CO2 , 100 % humidity 
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atmosphere. For sequential passage, non-confluent cells were rinsed with a Ca2+ /Mg2+ -
free Hank's balanced salt solution (Sigma, St. Louis, MO) and treated with 0.5 mg/mL 
trypsin for 2 min. Released cells were recovered by centrifugation. For [ Ca2+]i 
detennination, cells were trypsinized and resuspended in HBSS at a density of 
approximately 106 cells/mL. 
Expression ofmurine agouti cDNA: A 707 hp EcoRV/Pstl fragment of the full 
length agouti cDNA (6) was subcloned into a Smal/Pstl site in the baculoviral expression 
vector pVLI 393 (Pharmingen, San Diego, CA) and the construct was verified by 
sequencing. This construct was then packaged and titered using standard methods (21 ). 
Trichiplusia ni ( T. ni) cells were then infected at a multiplicity of infection of 2, and the 
medium was collected 48 hr after infection. This medium was then filtered with a 5 kDa 
cutoff Sartorius filter and used directly ("agouti-conditioned medium"). Controls 
consisted of medium alone and medium collected 48 hr after infection from T. ni cells 
infected with the wild-type baculovirus ("control medium"). Rabbit anti-peptide 
antibodies were generated against a fragment of murine agouti comprising the predicted 
amino acid residues from position 25 to position 40 ( 6). Samples of control and 
conditioned medium were electrophoresed on a 4-20 % SOS/PAGE gel and blotted to 
nitrocellulose. Western blots were performed with the agouti antipeptide antibody in 50 
mM Tris, pH 7.5/150 mM NaCV3 % BSA (fraction 5, Sigma, St. Louis, MO) at a I :500 
dilution. The second antibody was goat anti-rabbit IgG conjugated to alkaline 
phosphatase at 1 :3000. 
76 
Northern blot analysis: Total cellular RNA from all tissues was extracted by using 
the guanidine thiocyanate procedure (22), enriched for poly(Af RNA by using an 
oligo( dT)-cellulose column (23), electrophoresed through formaldehyde gels, and blotted 
to GeneScreen (DuPont) by standard procedures (22). The radiolabeled agouti probe (6) 
was prepared with the random hexamer labeling technique (24). Posthybridization filter 
washes were conducted at high stringency (in 0.03 M NaCV0.003 M sodium citrate/0. 1  % 
sos at 68 °C). 
[Ca2+li determination: [Ca2+]i levels in freshly isolated soleus and gastrocnemius 
myocytes and in suspensions ofL6 myocytes were determined spectrofluorometrically in 
fura-2 loaded cells as previously described (25, 26). Briefly, cell suspensions were loaded 
with fura-2-acetoxymethyl ester in the dark for 20 min at 37 °C with shaking, washed with 
HBSS, and resuspended immediately prior to [Ca2+)i determination. [Ca2+]i was measured 
by using dual excitation (340 and 380 run) and single emission (5 10  run) tluorometry. 
Digitonin (25 µM) and Tris/EGTA (both 100 mM, pH 8.7) were used to determine 
maximal and minimal fluorescent ratios, respectively, and [Ca2+]i was then calculated from 
fluorescent ratios using the equation of Grynkiewicz et al. (27). To evaluate the effects of 
the agouti-conditioned medium, cells were preincubated in a I :9 (v/v) mixture of 
conditioned or control medium and HBSS for 40 min, washed, resuspended and loaded 
with fura-2 as above. 
45Ca2+ efflux and influx: Soleus 45Ca2+ efflux and influx were determined by using 
slight modifications of methods previously described (28). For efflux, the soleus was 
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loaded with 45Ca2+ by incubation in a physiological salt solution (PSS) containing I µCi 
(3 7 kBq) 45Ca2+ /mL while being gassed with 95 % CQ.,/5 % 02 at 3 7 °C. The washout of 
radioactivity into unlabelled PSS was then followed with 3 min intervals for 90 min. 
45Ca2+ efflux was expressed as a percentage of the original 45Ca2+ load remaining in the 
tissue at each time point (28), and the Ca2+ efflux rate constant was then calculated from 
the 45Ca2+ efflux curve. To determine Ca2+ influx, soleus segments were equilibrated in 
PSS for IO min at 3 7 °C while being gassed with 95 % C02'5 % 02. They were then 
transferred to PSS containing I µCi 45Ca2+/mL for 2-10 min to measure rate ofCa2+ influx. 
Statistical analysis: Comparisons between A� la and ala mice or between agouti­
conditioned and control medium were evaluated via Student's t test. Comparisons among 
black, pseudoagouti, mottled and yellow animals were evaluated via one-way analysis of 
variance. The effects of agouti-conditioned versus control medium on [Ca2+]i in the 
presence or absence of extracellular Ca2+ were assessed by two-way (incubation medium x 
treatment) analysis of variance. The relationship between [ Ca2+]i and body weight was 
determined via linear regression analysis. 
D. Results 
To evaluate the effect of the ectopic expression of the agouti gene on [Ca2+]i, we 
chose to use mice carrying the A� mutant allele as our model animal. A�la mice are 
especially well suited for these experiments because the agouti gene is ectopically 
expressed at various levels in individual animals, and the level of agouti expression 
correlates with the degree to which the animals express the mutant phenotype (Fig. I ). 
For example, A� I- mice with high or moderate levels of ectopic agouti expression have 
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Figure 1 .  Northern blot analysis of agouti locus expression in various tissues from adult 
viable yellow (A'VY/a) mice exhibiting either a completely pseudoagouti, moderately mottled 
(pseudoagouti plus yellow mix), or solid yellow coat color. Neonate skin from a day 5 
wild-type agouti (A/A) mouse was included as a positive control. A wild-type agouti 
cDNA clone was 32P-labeled and hybridized to these poly (Af RNAs (2. 5 µg per lane, 
except for the following: mottled skin, 1 .4 µg; mottled muscle, 2.0 µg; and yellow skin, 
2.0 µg). 
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completely yellow fur or are mottled with patches of agouti-like hair mixed with totally 
yellow hair, respectively; these animals have a high propensity to develop the obesity and 
hyperinsulinemia traits. On the other hand, mice that ectopically express agouti at very 
low levels have a coat color that is similar to the wild-type agouti color and are referred to 
as pseudoagouti. Pseudoagouti mice have normal body weights and are not 
hyperinsulinemic, suggesting that there may be a threshold level at which agouti exerts 
these effects. Therefore, the effect of agouti on [Ca2+]i and insulin resistance can be 
studied in sibling A"" I- mice that differ only in their level of agouti expression, and their 
coat colors provide a general indication of the level of ectopic agouti expression and their 
propensity to become obese and hyperinsulinemic. 
This study was conducted in a muscle consisting primarily of insulin-sensitive type 
I muscle fibers ( soleus) as well as in a muscle containing primarily less insulin-sensitive 
type II fibers (white gastrocnemius). Collectively, A""la of both genders exhibited 37 % 
greater soleus [Ca2+]i compared to non-agouti black controls (p < 0.0 1 ). However, this 
difference was dependent upon the degree of phenotypic expression of the A"" genotype; 
soleus [Ca2+]i in the pseudoagouti animals was not significantly different from that in ala 
mice, whereas a two-fold elevation was found in the yellow mice (Table 1 ). The mottled 
A""la animals exhibited levels only slightly lower than the yellow mice. These variations in 
[Ca2+]i closely tracked the heterogeneity in body weight, and there was a high degree of 
correlation between the two (r = 0.9 1 ,  p < 0.0 1 ;  Fig. 2). These data are also consistent 
with the previous observations that pseudoagouti mice do not become obese, whereas 
both mottled and yellow mice have the propensity to become severely obese. 
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Table I .  [Ca2+]i and Ca2+ flux in non-agouti black (ala) and viable yellow (AY1/a) mice 
with various levels of ectopic agouti expression 
Measurement 
[Ca2+]i, nM 
Soleus 
Gastrocnemius 
45Ca2+ flux (Soleus) 
Efflux rate1 
Influx rate 1 
Nonagouti 
black mice 
174 ± 6 
293 ± 28 
1 1 .9 ± 3 .2 
1 1 5 ± 28 
Data are reported as mean ± SE. 
ND, no data 
Viable yellow mice 
Pseudo­
agouti 
177 ± 8 
283 ± 29 
ND 
ND 
Mottled 
308 ± 35• 
476 ± 361 
ND 
ND 
Yellow 
330 ± 391 
350 ± 40 
I O. I ± 1 .8 
1 66 ± 321 
1Unit for the efflux and influx rates are as follows: efflux, min·1 ; influx, cpm/ng of 
protein/min 
1p < 0. 0 I vs. non-agouti black mice 
8 1  
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Figure 2 .  Relationship between body weight and [Ca2+]i in freshly isolated soleus 
myocytes from viable yellow (A vy /-) mice with either a pseudoagouti, mottled or yellow 
coat color. There is a significant correlation (r = 0.91, p < 0.01; n = 18) between [Ca2+]i 
and body weight. 
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In gastrocnemius, [Ca2+]i was increased only in male mottled and yellow mice 
compared to the non-agouti control black mice (Table 1 ), and there was no significant 
relationship between body weight and [Ca2+]i in this muscle type (data not shown). 
To evaluate the cause of the increased [Ca2+]i, Ca2+ efflux and influx studies were 
conducted in soleus. Basal Ca2+ efflux rate was not significantly different between A"' la 
and ala mice (Table 1 ), although insulin-stimulated efflux was diminished ( data not 
shown), consistent with a diminution in Ca2+ -A TPase activity in insulin resistance (26, 28, 
29). In contrast, the basal Ca2+ influx rate was significantly increased in A "'la mice (Table 
1 ). 
To directly evaluate the role of the agouti gene product in regulating skeletal 
muscle [ Ca2+]i, we prepared conditioned media containing recombinant agouti protein. 
For this purpose, the wild-type agouti cDNA was subcloned into a baculoviral expression 
vector and T. ni cells were infected with either the agouti expression baculovirus or a 
wild-type baculovirus control. The medium collected from T. ni cells infected with the 
agouti expression baculovirus produced a polypeptide that reacted against an agouti anti­
peptide antibody (Fig. 3). The controls, including medium collected from mock-infected T. 
ni cells and medium collected from T. ni cells infected with a wild-type baculovirus, 
showed no such immunoreactive species. In the agouti-conditioned medium, the antibody 
was completely blocked by incubation with the peptide antigen (data not shown), and the 
preimmune serum did not react with the agouti-containing medium. Additionally, the 
medium had agouti biological activity, since it was used to antagonize the ability of a­
MSH to stimulate cAMP production in B 16fl O melanoma cells (7) . 
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Figure 3 .  Expression of the murine agouti peptide. Ten micrograms of medium protein 
from T. ni cells 48 hr after infection of either a wild-type baculovirus or the agouti 
expression baculovirus was loaded onto a 4-20% SDS/P AGE gel (NOVEX, San Diego) 
and silver-stained. A duplicate gel was transferred to nitrocellulose and probed with either 
an agouti anti-peptide antibody or preimmune antibody. (Left) Silver-stained gel of the 
conditioned medium. The agouti polypeptide is not readily apparent. (Right) Western blot 
of a duplicate gel. The anti-agouti peptide antibody detects a protein of 21  kDa. 
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Because the medium is highly fluorescent, acute effects of agouti-conditioned 
medium on [Ca2+]i were not studied. Instead, L6 myocytes or freshly isolated myocytes 
were incubated in agouti-conditioned or control medium for 40 min and washed, and 
thenbasal [Ca21i of the cells was measured. This 40-min incubation period prior to [Ca2+]i 
measurement was comparable to the time required to isolate and study mouse soleus and 
gastrocnemius myocytes. The agouti-conditioned medium caused a significant increase in 
[Ca2+]i in L6 cultured myocytes (Table 2) and in soleus myocytes isolated from non-agouti 
black mice (data not shown). However, myocytes isolated from A,,,,la mice, in which 
[Ca2+]i was already elevated, exhibited no further increase after incubation in agouti­
conditioned medium (data not shown). Agouti-mediated increases in [Ca2+]i were 
dependent upon extracellular Ca2\ as no such increase was found in Ca2+ -free HBSS 
(Table 2). 
E. Discussion 
Although the genetic defect in yellow obese mice involves the ectopic expression 
of the agouti gene, it was previously unclear which tissues were responding specifically to 
the agouti gene product in a manner that causes the obesity and hyperinsulinemia/insulin 
resistance. It was also unknown how the agouti protein was effecting a response at the 
cellular level. Here we have determined that adult A,,,, la mice exhibit significant increases 
in soleus Ca2+ influx and [Ca2+]i, and that these increases correspond with ectopic agouti 
expression and obesity. Moreover, conditioned medium containing recombinant agouti 
protein stimulated significant increases in [Ca2+]i in both freshly isolated and cultured 
skeletal myocytes. These data provide compelling evidence to support a direct role of 
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Table 2. Effects of agouti-conditioned medium on [Ca2+]i in L6 cultured skeletal 
myocytes in the presence or absence of extracellular Ca2+ 
Treatment 1 
Ca2+ -containing 
Ca2+-free 
1n = 8 per group 
•p < 0.0 1 
Control-conditioned 
84.8 ± 3 .3 
88.7 ± 4.0 
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Medium 
Agouti-conditioned 
123 .2 ± 4.8· 
95.7 ± 2.7 
agouti in modulating soleus responses to insulin. Accordingly, the action of agouti on 
type I muscle fibers in the yellow obese mutants may contribute to their insulin resistance. 
Although the A"" la mice exhibited a decrease in insulin-stimulated soleus Ca1+ 
efflux, there was no decrease in basal efflux. This is consistent with our previous 
observations in rat aortic smooth muscle, in which impaired Ca2+-ATPase-mediated Ca1+ 
efflux was a result, rather than a cause, of insulin resistance (30-32). In contrast, the A"'la 
mice did exhibit an increase in Ca1+ influx. Therefore, increased [Ca1+]i in mice carrying 
the A"' allele of agouti appears to result from an increase in Ca1+ influx rather than from 
either an impairment in Ca2+ efflux or an increase in Ca1+ release from sarco/endoplasmic 
reticulum stores. This suggestion is further supported by the observation that the increase 
in [Ca1+]i in L6 skeletal myocytes in response to incubation in agouti-conditioned medium 
was dependent upon extracellular Ca1+ and did not occur in a Ca1+-free HBSS. However, 
it is also possible that agouti-mediated effects on receptor interactions may be dependent 
upon the presence of extracellular Ca1+. 
Several lines of evidence support a role for Ca1+ in modulating tissue insulin 
sensitivity. Draznin et al. (13) demonstrated an optimal range of [Ca2+]i for maximizing 
insulin-stimulated glucose transport, with elevations beyond this range causing marked 
decreases in adipocyte insulin sensitivity. Similarly, data from a number of studies indicate 
that increasing [Ca1+]i in isolated adipocytes results in significant inhibition of insulin­
stimulated glucose transport ( 17-19) and oxidation ( 14). In addition, Ca1+ entry blockade 
in obese elderly humans resulted in significant increases in peripheral insulin sensitivity 
(15, 16). Finally, Resnick et al. (33) reported that obese patients exhibited a 41 % 
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increase in [ Ca2+]i compared with their lean counterparts. Moreover, there was a 
significant positive correlation between erythrocyte [ Ca2+]i and body mass index in lean 
and obese subjects, similar to the correlation between soleus muscle [Cal+]i and body 
weight observed in the present study (Fig. 2). 
While the relationship between [Cal+]i and insulin signal transduction is not well 
understood, it appears that elevations in [Ca2+]i may, in part, result in insulin resistance by 
affecting the phosphorylation of glucose transporter type 4 ( Glut 4) and other insulin 
sensitive substrates within the cell ( 17- 19). Glut 4 is the primary insulin-responsive 
glucose transporter in the cell and its activity is regulated by serine phosphorylation (34 ). 
Normally, insulin activates phosphoserine phosphatase 1 (PPl}, which dephosphorylates 
and, hence, activates Glut 4 (34). Recently Reusch et al. ( 1 7) reported that K+ 
depolarization or parathyroid hormone treatments increased [Cal+]i in isolated adipocytes, 
and that this appeared to result in an increased phosphorylation of Glut 4. This effect was 
likely due directly to changes in [Cal+]i because treatment with nitrendipine, which blocks 
entry of Cal+ into the cell, maintained normal Glut 4 levels of phosphorylation. These 
effects of increased [Cal+]i on phosphorylation of Glut 4 appeared to be mediated by Cal+ -
induced phosphorylation and activation of inhibitor I ,  which functions to inhibit PP I 
activity ( 18). Overall, based on these findings, we predict that the hyperinsulinemia/insulin 
resistance in the yellow obese mutants causes increased [ Cal+]i in soleus muscle which 
induces increased activity of inhibitor 1 .  This effect leads to an increase in 
phosphorylation of PP I, which, in turn, results in an increased phosphorylation and 
inactivation of the insulin-responsive substrates within the cell, including Glut 4. 
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Experiments to directly evaluate the activity of Glut 4 and the other insulin responsive 
components in the cell will help to confirm this prediction. 
While the ectopic expression of agouti causes changes in [Ca2+]i, it remains unclear 
how specifically agouti is signaling the responses in soleus muscle described in this report. 
Within the hair follicle, agouti acts as an antagonist for the binding of a-MSH to its 
receptor on the melanocyte (7). In this manner, it prevents the a-MSH-induced increases 
in the level of cAMP within the cell (7), and hence elicits its biological action. Since the 
a-MSH receptor does not appear to be expressed in skeletal muscle (35), agouti cannot be 
acting in exactly the same manner in muscle as it is in the hair follicle. Another member of 
the melanocortin receptor family, melanocortin 5 receptor (MC5R), is expressed on 
skeletal muscle (36). Therefore, it is possible that agouti is functioning on the MC5R in 
soleus muscle in a manner similar to that which occurs with the a-MSH receptor in the 
hair follicle. Alternatively, agouti may act through an interaction with another as yet 
unidentified receptor, or possibly by upregulating voltage- and/or receptor-operated Ca2+ 
channels within the cell. Additional experiments utilizing purified recombinant agouti 
protein should help to address this issue. 
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II. AGOUTI INDUCED ELEVATION OF INTRACELLULAR CALCIUM. 
APP ARENT INTERACTION WITH MELANOCORTIN RECEPTORS 1 
A. Abstract 
Several dominant mutations at the murine agouti locus cause a syndrome of 
marked obesity and insulin resistance. We recently reported that intracellular free calcium 
([Ca2+]i) is elevated in viable yellow mice. Since [Ca2+]i has a key role in the pathogenesis 
of insulin resistance, obesity and hypertension, the role of the purified agouti gene product 
in regulating [Ca2+]i was evaluated in a number of cell types. Purified murine agouti 
induced slow, sustained increases in [Ca2+]i in L6 skeletal myocytes, A7r5 vascular 
smooth muscle cells and 3 T3-L I adipocytes in a dose-dependent fashion. In L6 skeletal 
myocytes, agouti stimulated an increase in [Ca2+]i with an apparent EC,o of 62 nM. This 
response was substantially inhibited by Ca2+ entry blockade with nitrendipine. To 
determine if melanocortin receptors may play a role in agouti regulation of [Ca2+]i, we 
examined the effect of melanocortin peptide and agouti in cells stably transfected with 
human melanocortin receptors . Human embryonic kidney 293 (HEK-293) cells 
transfected with either the human melanocortin I or melanocortin 3 receptor responded to 
human agouti with slow, sustained increases in [Ca2+]i, while non-transfected HEK-293 
cells did not respond to agouti. This direct effect of agouti on stimulating increases in 
[Ca2+]i suggests a potential mechanism for agouti-induced insulin resistance. 
1This manuscript has been submitted for publication in similar form with co-authors 
Kiefer, L. L., Woychik, R. P., Wilkison, W. 0., Truesdale, A., lttoop, 0., Willard, D., 
Nichols, J. and Zemel, M. B. in : Am. J. Physiol. 
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B. Introduction 
Insulin resistance is characterized by abnormal intracellular Ca1+ ([Ca1+]i) 
homeostasis in several types of cells including skeletal myocytes, vascular smooth muscle 
cells, and adipocytes (1-3). Increasing [Ca1+]i level in the cell inhibits insulin-stimulated 
glucose transport and Ca2+ channel antagonism improves cellular insulin sensitivity ( I ,  3). 
Increased [Ca2+]i may contribute to insulin resistance by inhibiting the dephosphorylation 
of insulin-sensitive substrates, including glycogen synthase ( 4) and the insulin-sensitive 
glucose transporter (Glut 4) (5); this may result from Ca1+-induced phosphorylation and 
activation of inhibitor- I ,  thereby blocking the activation of phosphoserine phosphatase- I 
(6). It is also possible that Ca1+ -mediated increases in activity of protein kinase C may 
contribute to insulin resistance via phosphorylation of the insulin receptor J3-subunit 
tyrosine kinase (7). 
Dominant mutations at the agouti locus in the mouse such as lethal yellow (A' ) 
and viable yellow (A") are obese and exhibit hyperinsulinemia at 5-6 week of age, prior to 
becoming significantly heavier than control (8, 9). Molecular analyses reveal that these 
mice ectopically express wild-type agouti transcripts, and that this is due to a mutation in 
the promoter region of the agouti gene (10-12). Transgenic mice in which the wild-type 
agouti cDNA is placed under the transcriptional control of ubiquitous gene promoters not 
only express the agouti mRNA in multiple tissues but also develop obesity, 
hyperinsulinemia, hyperglycemia and yellow coat color, demonstrating that ectopic 
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expression of agouti per se is responsible for the diseases associated with dominant agouti 
alleles (13). 
While the ectopic expression of agouti is responsible for the dominant pleiotropic 
effects ( e.g. obesity and insulin resistance) characteristic of A"" mice, the mechanism of 
agouti action and its target tissue remains unclear. However, the mechanism of agouti 
regulation of mouse coat color has been described ( 14) and may serve as a paradigm for 
investigating the mechanism of agouti's effects on insulin sensitivity and obesity. 
Melanocytes in the hair bulb produce two types of pigment; eumelanin (black) and 
phaeomelanin (yellow), and normally, synthesis of the pigment can be switched between 
the two types (15). Melanocytes begin to produce eumelanin when a-melanocyte 
stimulating hormone (a-MSH) binds to its receptor on the cell membrane, stimulating 
adenylate cyclase (16). The agouti gene product antagonizes the binding of a-MSH, 
causing melanocytes to produce phaeomelanin (14). Receptors for several members of the 
melanocortin family have been identified, although their functions remain unclear. 
Accordingly, it is possible that similar inhibition of melanocortin peptide binding to one or 
more of these receptors may be responsible for the dominant pleiotropic effects of agouti. 
We have recently demonstrated that AYJ' mice exhibited a marked elevation of 
skeletal muscle [Ca2+]i which was highly correlated with the degree of ectopic 
overexpression of agouti and obesity ( 17). Further, we reported that incubation of 
cultured skeletal myocytes with media containing recombinant murine agouti protein 
caused an increase in steady-state [ Ca2+]i, and that this may contribute to the insulin 
resistance characteristic of mutations at the mouse agouti locus (17). 
95 
Consequently, we conducted this study to determine (a) the effects of purified 
recombinant agouti protein on [Ca2+]i in several distinct cell types, and whether (b) 
melanocortin receptors play a role in agouti mediated Ca2+ signaling. We report herein 
that the recombinant murine agouti protein induced elevation of [Ca2+]i in L6 skeletal 
myocytes, A7r5 vascular smooth muscle cells and 3T3-Ll adipocytes, and that this effect 
is sensitive to Ca2+ -channel blockade. Further, agouti regulation of [Ca2.]i appears to be 
modulated by melanocortin receptors in human embryonic kidney 293 cells (HEK-293 
cells), although the role of melanocortin receptors in other cell types is not clear. This 
suggests that agouti may regulate [Ca2.]i in some tissue types via interaction with 
melanocortin receptors. 
C. Materials and Methods 
Cell culture: The spontaneously fusing L6 skeletal myocytes (ATCC, Bethesda, 
MD) were grown in 75-cm2 flasks in Dulbecco's modified Eagle's medium with IO % 
glucose (DMEM) supplemented with 5 % fetal bovine serum (FBS) (v/v) , 5 % calf serum 
supplemented iron-enriched (CS) (v/v), and antibiotics (50 units of penicillin/mL and 5 µg 
of streptomycin/mL ). Cultures were maintained in continuous passages ( < 20) by 
trypsinization (0.05 % trypsin) of semiconfluent nonfused cells. A7r5 vascular smooth 
muscle cells (ATCC, Bethesda, MD) were grown in the same conditions as that for L6 
cells. 3T3-Ll cells (ATCC, Bethesda, MD) were grown in 100 mm dishes in DMEM 
containing IO  % FB S and antibiotics. For differentiation of fibroblasts into adipocytes, 
confluent cells were incubated in DMEM/FBS containing 0.5 mM isobutylmethylxanthine 
(IBMX) (Sigma, St. Louis, MO) and 0.25 µM dexamethasone (DEX) (Sigma, St. Louis, 
% 
MO) for 60 hr and then IBMX and DEX were removed and cells were remained in 
DMEM/FBS. Non-transfected HEK-293 cells were grown in 75-cm2 flasks in DMEM 
containing 1 0  % FBS and antibiotics. Transfected HEK-293 cells were maintained in 
DMEM/FBS with 250 µg/mL geneticin and compared with non-transfected HEK-293 
cells. All types of cells were maintained at 37 °C in an atmosphere containing 5 % CO2 
and 1 00  % humidity. Cell culture reagents, FBS, CS, and Trypsin-EDTA were from 
Gibco/BRL (Grand Island, NY). 
Production and purification of recombinant agouti polypeptide: A 6 14  bp 
Xbal/Pstl fragment of the full-length mouse agouti cDNA (I 0, 1 1 ) or human agouti cDNA 
( 1 8) was subcloned into a Xbal/Pstl digested baculoviral expression vector pAcMP3 
(PharMingen, San Diego, CA). Virus incorporating this vector were produced by 
standard methods ( 14). Spodoptera frugiperda cells (Sf-9) were propagated in Grace's 
supplemented medium containing 10 % CS and 0. 1 % pluronic F-68 and used to produce 
high-titer viral stocks. Fifteen liter scale production runs of murine or human agouti were 
produced by using Trichoplusia ni (T. ni) cells adapted to suspension (JRH Biosciences, 
Woodland, CA). T. ni cells were infected 24 hr post-seeding at a density of 1 x 1 06 
cells/mL at a multiplicity of infection of 1 .  Conditioned media from infected cells were 
harvested 48 hr after infection, filtered through a Whatman 3 filter, and purified as recently 
described ( 1 9). 
Transfection with receptor genes: The coding region of the human melanocortin 1 ,  
3 and 5 receptors (hMCl -R, hMC3-R and hMC5-R) genes were amplified by polymerase 
chain reaction (PCR) and subcloned into the vector pMT 4 and sequence was verified. 
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HEK-293 cells which appear to lack endogenous melanocortin receptors ( 14) were co­
transfected with pMT4 and pRSV-Neo by either calcium phosphate co-precipitation 
method or the use ofTransfectam Reagent (Promega). Clones were selected using 600 
µg geneticin/mL culture media. Using 1251-labeled Nle4-D-Phe7 -a-MSH (NDP-MSH) 
(Bioscience Inc. King of Prussia, PA), the Ki for the clones ranged from 1 . 1  x 1 0·10 M to 
5 .8  x 1 0·10 M. Of these clones the receptor number per cell was determined for MC I -R 
clone, and demonstrated to be approximately 1 8,000 receptors per cell. 
Measurement of [Ca2+]i : [Ca2+]i was measured in L6, A 7r5 and HEK-293 cells as 
previously described ( 1 7), and in 3T3-Ll  cells as described by Klip et al. (20). 
Monolayers of non-fused L6 cells and confluent A 7r5 cells after 14- 16  hr starvation in a 
serum-free culture media were rinsed with Hank's solution (Gibco/BRL, Grand Island, 
NY) and detached by incubation in 2 mL of trypsin (0.05%) for 2-3 min at 37 °C and 
released by pipetting with culture media containing FBS. Confluent HEK-293 cells after 
3-4 hr starvation in a serum-free culture media were released just by pipetting without 
trypsinization. Cells were harvested by centrifugation at 50 x g, and resuspended in 1 mL 
ofHEPES-butfered salt solution (HBSS) ( 1 7) at a density of approximately 1 06 cells/mL. 
For 3T3-Ll cells, monolayers of differentiated cells were rinsed with serum-free DMEM 
and exposed to 0.05 % trypsin for 3 min. The solution was decanted, and the cells were 
incubated for 3 min in culture media. Cells were detached by pipetting and collected by 
centrifugation at 50 x g. Cells were then incubated in culture media to recover for 1 hr 
followed by incubation in serum-free DMEM for 4 hr at 37 °C in an atmosphere of 5 % 
CO2 , and collected by centrifugation and resuspended in HBSS at a density of 
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approximately 106 cells/mL. Cell suspensions were chilled in ice for 5 min and loaded 
with 10 µM fura-2/AM (final concentration) (Sigma, St. Louis, MO) in the dark for 20 
min at 37 °C. For 3T3-Ll adipocytes chilling step was skipped. Extracellular fura-2/AM 
was washed three times with HBSS by centrifugation. For the [Ca2+]i measurements L6, 
A7r5, HEK-293 cells and 3T3-Ll cells were resuspended in 1 mL ofHBSS and 
transferred to a 1-mL, 37 °C cuvette. [Ca2+]i levels were then measured fluorometrically 
in suspensions using dual excitation (340 and 380 nm)/single emission (510 nm) 
fluorometry as previously described (17) and [Ca2+]i was then calculated by the computer 
in the fluorometer using the equation of Grynkiewicz et al. (21). [Ca2+]i response to the 
recombinant agouti protein or to NDP-MSH was evaluated after establishing a stable 
baseline for each cell suspension. In experiments with Ca2+ channel blocker, after loading 
fura-2/AM cells were pretreated with nitrendipine (RBI, Natick, MA) (30 µM, final 
concentration) for 10 min at 3 7 °C prior to adding agonists. 
Statistical analysis: All data were analyzed in the student's t test or, where 
appropriate, analysis of variance. Data were evaluated for equality of variance and 
normality of distribution prior to statistical analyses were confirmed. Data were reported 
as mean ± SE. 
D. Results 
Purified recombinant murine agouti protein induced a slow, sustained increase in 
[Ca2+]i (p < 0.01 vs. baseline) in L6 skeletal myocytes and A7r5 vascular smooth muscle 
cells (Fig. 4). Murine agouti also produced a slow, sustained increase in [Ca2+]i in fully 
differentiated 3T3-Ll adipocytes. For example, 50 nM agouti increased [Ca2+]i by 44 ± 4 
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Figure 4. Effects of recombinant murine agouti protein ( 50 nM) on intracellular Ca2+ 
levels ([Ca2+]i) in cultured (A) L6 skeletal myocytes and (B) A7r5 vascular smooth muscle 
cells. [Ca2+]i levels were measured as described in materials and methods. Agouti was 
added at times designated by the arrows. 
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nM over the baseline at 200 sec following agouti addition and reached at plateau of 73 ± 6 
nM increase at 400 sec following agouti addition (p < 0.03 vs. vehicle and time controls). 
These data are summarized in Table 3. 
The agouti effect on [Ca2•]i was further characterized in L6 skeletal myocytes. 
The [Ca2+]i dose-response to agouti is shown in Fig. 5; agouti stimulated [Ca2.]i 
responses with an apparent ECso of 62 ± 19 nM. Ca2• channel blockade with 30 µM 
nitrendipine reduced the response to 50 nM agouti in these cells by approximately 50 % (p 
< 0.01), from 49 ± 8 to 22 ± 6 nM. 
Agouti regulates coat color via antagonism of a-MSH binding to the a-MSH 
receptor (MCl-R). Since melanocortin peptides also stimulate [Ca2.]i increases, we 
wanted to evaluate whether the effect of agouti on [Ca2.]i was also mediated through 
melanocortin receptors; we first measured the [Ca2.]i response to NDP-MSH, a stable and 
potent analogue of a-MSH, in HEK-293 cells stably transfected with hMC 1-R, hMC3-R, 
hMC5-R and in non-transfected HEK-293 cells. NDP-MSH (1-10 nM) induced 
significant. transient elevations in [Ca2+]i in HEK-293 cells transfected with hMC 1-R, 
hMC3-R and hMC5-R (p < 0.01 vs. baseline, Fig. 6), but not in non-transfected HEK-293 
cells ( data not shown). Also, NDP-MSH in concentrations as high as 500 nM failed to 
stimulate an increase in [Ca2+]i in L6 or A7r5 cells (data not shown). Thus, as previously 
described, melanocortin peptide is capable of stimulating transient increases in [Ca2+]i in a 
melanocortin receptor-dependent manner. 
We then examined what agouti 's effect on [Ca2.]i would be in these melanocortin 
receptor transfected cell lines. As shown in Table 4, agouti (20 nM) provoked an increase 
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Table 3 .  Effects of purified recombinant murine agouti protein on [Ca2+]i in L6 skeletal 
myocytes, A7r5 vascular smooth muscle cells (VSMCs) and 3T3-Ll adipocytes 1 
[Ca2+]i Increase over Baseline (nM) 
L6 Myocytes 
A7r5 VSMCs 
3T3-L I Adipocytes 
25 nM Agouti 
32 ± 1 ·  
46 ± 9 • 
33 ± 6 • 
1Data shown are at 400 sec following agouti addition. 
•p < 0.03 vs. vehicle control 
bp < 0.03 vs. 25 nM agouti 
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50 nM Agouti 
49 ± 8 a, b 
74 ± 6 a, b 
73 ± 6 a, b 
---100 
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Figure 5 .  Dose-response curve of effects of recombinant murine agouti protein (mAgouti) 
(nM) on intracellular Ca2+ levels ([Ca2+]i) in cultured L6 skeletal myocytes. [Ca2+]i 
responses were measured as described in materials and methods, and values reported are 
for the response plateau at 400 sec following agouti addition . The data were fit by non­
linear least squares analysis, yielding an half-maximal concentration (EC50) of 62 ± 19. 
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Figure 6. Effects of NDP-MSH ( 1 - 1 0  nM) on intracellular Ca2+ levels ([Ca2+]i) in human 
embryonic kidney 293 cells transfected with (A) hMC I -R ( I  nM), (B) hMC3-R ( 10  nM), 
or (C) hMCS-R ( 10  nM). [Ca2+]i levels were measured as described in materials and 
methods. NDP-MSH was added at times designated by the arrows. 
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Table 4. Effects of purified recombinant human agouti protein on [Ca2+]i in human 
embryonic kidney 293 (HEK-293) cells transfected with melanocortin receptors1 
HEK-293 
HEK-293-hMCIR3 
HEK-293-hMC3R3 
HEK-293-hMC5R3 
* No detectable increase 
[Ca2+]i Increase over Baseline (nM)2 
• 
• 
1Data shown are at 400 sec following agouti addition. 
2Response to 20 nM recombinant human agouti protein 
3hMC IR, human melanocortin I receptor; hMC3R, human melanocortin 3 receptor; 
hMC5R, human melanocortin 5 receptor. 
•p < 0. 0 I vs. baseline 
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in [Cal+]i over the baseline in the hMC 1-R and hMC3-R HEK-293 cell lines, while no 
response was observed in either the hMCS-R or non-transfected HEK-293 cells. 
Further characterization of this response was performed by using a dose response 
of recombinant human agouti protein on [Cal+]i in the hMCl-R line (Fig. 7). Agouti 
stimulated [Cal+]i with an approximate EC50 of 18 ± 0.07 nM. 
E. Discussion 
Data from the present study directly demonstrate that recombinant murine agouti 
protein elicits significant increases in [Cal+]i in several distinct cell types, including L6 
skeletal myocytes, A7r5 vascular smooth muscle cells and 3T3-Ll adipocytes. These 
agouti effect on [Cal+]i were manifested as a gradual, sustained increase rather than a 
rapid transient, and is in part dependent upon Cal+ channel mediated Cal+ influx, 
consistent with our recent report of increased skeletal muscle Cal+ influx in A"' mice (17). 
This is also consistent with other Cal+ agonists which inhibit insulin signaling. For 
example, Kelly et al. (22) reported that treatment of adipocytes with agonists which either 
produced sustained increases in [Cal+]i or biphasic responses with a sustained component, 
such as norepinephrine or KCl, resulted in significant inhibition of insulin-stimulated 
glucose transport. In contrast, oxytocin in concentrations sufficient to cause 3-5 fold 
increases in [Cal+]i which were transient rather than sustained, similar to those found with 
NDP-MSH in the present study, were without effect on insulin action. Moreover, an 
additional common feature of those agonists which were able to inhibit insulin signaling 
was that they promoted Cal+ influx, and there was a high degree of correlation (r = 0.92) 
between the sustained [Cal+]i response to these agonists and the degree of inhibition of 
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Figure 7. Dose response curve of the effects of recombinant human agouti protein 
(hAgouti) (nM) on intracellular Ca2+ levels ([Ca2+]i) in human embryonic kidney 293 cells 
transfected with hMC I-R. [Ca2+]i responses were measured as described in materials and 
methods, and values reported are for the response plateau at 400 sec following agouti 
addition. The data were fit by non-linear least squares analysis assuming a single binding 
site, yielding an half-maximal concentration (EC5o) of 1 8  ± 0.07. 
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insulin action. It was suggested that this correlation was related to Ca2+ channel opening 
rather than to the actual increase in [Ca2+]i, as ionomycin caused a sustained elevation in 
[Ca2+]i which was derived from intracellular stores (22). Accordingly, net elevations in 
[Ca2+]i secondary to sustained agouti exposure may maintain a chronic excess in Ca2+ 
channel-mediated Ca2+ influx and thereby induce insulin resistance in A"' mice. 
Agouti-induced increases in [Ca2+]i in multiple cell types may result in tissue­
specific consequences. For example, since increased [Ca2+]i results in diminished insulin 
signaling { I ,  3), as discussed above, agouti-mediated elevations in [Ca2+]i are predicted to 
result in insulin resistance in skeletal myocytes and adipocytes. In vascular smooth muscle 
cells, Ca2+ plays a central role in both regulation of contraction and proliferation (3). 
Consequently, agouti-induced increases in vascular smooth muscle [Ca2+]i (as typified by 
A 7r5 cells) may contribute to the hypertension which is characteristic of obese, insulin­
resistant states. Indeed, our preliminary data indicate that vascular rings isolated from A">' 
mice exhibit exaggerated contractile responses to presser agonists (unpublished 
observation). 
In addition to contributing to insulin resistance, increased [Ca2+]i in adipocytes 
appears to stimulate lipogenesis. We have recently reported that incubation of3T3-Ll 
adipocytes in an agouti-containing medium upregulates fatty acid synthase (FAS) mRNA 
levels and activity (23). Moreover, these effects were reversed by Ca2+ channel blockade 
with nitrendipine and could be replicated by depolarization with 50 mM KCI (24 ). Thus, 
agouti-induced increases in [Ca2+]i appear to stimulate de novo lipogenesis and may 
thereby contribute to the obesity of A">' mice. This phenomenon may be relevant to human 
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obesity as well, as we have also found recombinant human agouti protein to stimulate an 
increase in [Ca1+]i in freshly isolated human adipocytes (unpublished observation). 
Although agouti regulation of [Ca1+]i appears to be primarily via Ca1+ channels, the 
mechanism of this Ca1+ regulation is unknown. However, agouti has recently been 
demonstrated to have significant spatial cysteine homology to both co-conotoxins and 
plectoxins, both of which have high affinity for neuronal Ca1+ channels (25). The action of 
co-conotoxin GVIA, one of the co-conotoxins from the venom of the marine snail Conus 
geogprhus, appears to be through direct interaction of the toxin with a receptor closely 
linked to an N-type Ca1+ channel, without a second messenger, followed by a very slow 
dissociation (26). Plectoxins, contained in venom produced by the spider Plectreurys 
tristis, inhibit N-type Ca1+ channels as well as unclassified Ca1+ channels, although the 
underlying mechanisms are unclear (27). The structural similarity of agouti protein with 
these two toxins suggests that agouti may represent a class of molecules related to the 
toxins that interact with a specific Ca1+ channel subtype or as of yet undefined Ca1+ 
channel (25). Consistent with this, we have reported that agouti-induced increases in 
[Ca1+]i are abolished in the absence of extracellular Ca1+ (I  7) and have also demonstrated 
inhibition by Ca2+ channel blockade with nitrendipine in the present study. 
Agouti regulation of [Ca1+]i may also depend upon an interaction with 
melanocortin receptors in HEK-293 cells. Several studies have demonstrated that 
melanocortin action is linked to [Ca1+]i as well as cAMP signaling (28, 29). For example, 
adrenocorticotropic hormone (ACTH) binding to its receptor in adipocytes stimulates 
both adenylate cyclase and increased [Ca1+]i, and both are required for ACTH-induced 
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lipolysis (28). Moreover, m-conotoxin inhibits Ca1• channels in ACTH target tissues, 
diminishing the biological effects of the hormone in several tissues, including adrenal 
glomerulosa cells (30), lymphocytes (31) and neuronal cells (32). Consistent with this, all 
melanocortin receptor transfected cells in the present study exhibited NDP-MSH 
stimulated increases in [Ca21i, and these cells also respond to a-MSH with an increase in 
cAMP (14). However, co-administration of agouti failed to inhibit the effects ofNDP­
MSH on [Ca1.]i in HEK-293 cells transfected with melanocortin receptors (data not 
shown), similar to the previous report in which agouti did not antagonize cAMP 
production in hMC3-R or hMC5-R transfected cells (14), suggesting that MCJ-R and 
MC5-R do not appear to be direct targets for agouti. In contrast, non-transfected HEK-
293 cells failed to respond to agouti, while HEK-293 cells transfected with either the 
hMC 1-R or hMC3-R exhibited significant [Ca1.]i responses. These data indicate that 
agouti regulation of [Ca1.]i in HEK-293 cells is dependent upon an interaction with 
melanocortin receptors. However, this interaction is clearly different from agouti 
regulation of coat color, which is dependent upon a competitive antagonism with a-MSH 
(14). However, the role of melanocortin receptors in agouti-mediated Ca1• signaling in 
other cell types requires further clarification. The only melanocortin receptor reported to 
be expressed in muscle cells is MC5-R (33). Consistent with this, NDP-MSH failed to 
elicit an [Ca2.]i response in either type of muscle cell (L6 and A7r5) examined in the 
present study. However, in the HEK-293 cells, presence ofMC5-R was not sufficient to 
permit agouti regulation of [Ca1.]i , while MC 1-R and MC3-R were sufficient. Thus, it is 
not yet clear whether Ca1• signaling in muscle cells is dependent upon the presence of 
1 10 
melanocortin receptors. Nonetheless, we have demonstrated that Ca2+ signaling in these 
cells is also not mediated by melanocortin receptor antagonism. 
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III. THE EFFECTS OF CALCIUM CHANNEL BLOCKADE ON AGOUTI-INDUCED 
OBESITY1 
A. Abstract 
We previously observed that obese viable yellow (A"') mice exhibited increased 
intracellular Ca2+ ([Ca21i) and fatty acid synthase (FAS) gene expression. Further, 
recombinant agouti protein increased both in cultured adipocytes, and these effects were 
inhibited by Ca1+ channel blockade. Accordingly, we determined the effect of Ca2+ channel 
blockade with nifedipine (1 g/kg diet for 30 days) on FAS and obesity in transgenic mice 
expressing the agouti gene in a ubiquitous manner. The transgenic mice were initially 
significantly heavier (30.54 ± 0.66 vs. 27.26 ± 0 .28 g; p < 0.001) and exhibited a 0.81 °C 
lower initial core temperature (p < 0.0005) and an approximately 2-fold increase in fat pad 
weights (p = 0.002), 7-fold increase in adipose FAS activity (p = 0.009), and 2-fold 
increase in plasma insulin level (p < 0.05) compared to control mice. Nifedipine treatment 
resulted in an 16 % decrease in fat pad weights (p < O. 007) and a 7 4 % decrease in 
adipose FAS activity (p = 0.03), normalized circulating insulin levels and insulin-sensitivity 
(p < 0.05), and transiently elevated core temperature in the transgenic mice, but was 
without effects in the control mice. These data suggest that agouti regulates FAS, fat 
storage and possibly thermogenesis, at least partially, via a [Ca1+]i dependent mechanism, 
and that Ca1+ channel blockade may partially attenuate agouti-induced obesity. 
1This manuscript has been submitted for publication in similar form with co-authors 
Mynatt, R. L., Moore, J. W., Woychik, R. P., Moustaid, N. , and Zemel, M. B.  in : FASEB 
J. 
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B. Introduction 
Mice with dominant mutations at the agouti locus, including lethal yellow (A") and 
viable yellow (A"') are characterized by obesity, insulin resistance, and yellow coat color 
(1, 2). The mouse agouti gene normally regulates differential pigment production in hair­
bulb melanocytes (3). Each melanocyte in the hair bulb switches between eumelanin 
(black) and phaeomelanin (yellow), producing the wild-type mouse coat color of a black 
hair with a subapical band of yellow (3). Agouti mutations disrupt this switching process 
and form a dominance hierarchy in which the dominant alleles produce a yellow coat and 
the recessive alleles produce a black coat (3). 
Although agouti is normally expressed in neonatal skin, dominant agouti mutations 
are characterized by ectopic overexpression of agouti through out life (2, 4, 5). This is 
due to mutations in the promoter/regulatory region rather than in protein-coding domain. 
For example, the AY mutation exhibits a structural deletion corresponding to all but the 
promoter and 5 '-noncoding first exon of an another gene, Raly, which is tightly linked to 
agouti. This results in overexpression of agouti in a ubiquitous manner under the control 
of the Raly promoter (6). Unlike A", the AV)' mutation contains an insertion of an 
intracistemal A particle element (IAP), which activates agouti expression by initiating 
transcription from a cryptic promoter found within the IAP long terminal repeats (7). In 
both cases, however, the result is ubiquitous expression of agouti mRNA. 
Transgenic mice designed to express the agouti coding portion in a ubiquitous 
manner also develop a syndrome of obesity, hyperinsulinemia, hyperglycemia and yellow 
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coat color, similar to A"' mutation, demonstrating that ectopic overexpression of the 
agouti gene is directly responsible for pleiotropic effects associated with dominant agouti 
mutations (8, 9). However, the mechanism linking this pigmentation gene to obesity has 
not yet been identified. 
Several lines of evidence indicated that intracellular Ca1+ ([Ca1+]i) appears to be 
involved in metabolic derangements, including obesity and insulin resistance ( I 0-12). 
Obese patients exhibited increased basal [Ca1+]i in adipocytes ( I 0), while increasing 
[Ca1+]i in rat adipocytes reduced insulin stimulated glucose transport (11). Further, Ca1+ 
channel blockade enhanced insulin sensitivity in obese and glucose intolerant subjects ( 12). 
We have recently reported an increase in the expression of fatty acid synthase 
(FAS), a key enzyme in de novo fatty acid synthesis, in A""la mice compared to lean 
controls (13). We have also reported that A""la mice exhibited an elevation both in steady 
state [Ca1+]i and in Ca1+ influx rate (14). This increase in [Ca1+]i was closely correlated 
with both the degree of ectopic expression of the agouti gene and body weight ( 14 ), 
suggesting the possibility of a causal relationship between [Ca1+]i and obesity mechanism 
in these animals. Furthermore, we have also found recombinant agouti protein to 
stimulate both mRNA levels and activity of FAS and to increase triglyceride accumulation 
in 3T3-Ll adipocytes. Moreover, agouti-mediated stimulation of FAS activity was 
completely prevented by Ca1+ channel blockade (13). Furthermore, agouti-stimulation of 
FAS was mimicked by stimulation ofCa1+ influx in 3T3-Ll adipocytes with other Ca1+ 
agonists, such as KCl or parathyroid hormone ( 15), suggesting that [Ca1+]i modulation 
may be an important means of regulating FAS. 
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Accordingly, Ca2+ channel antagonism in animals overexpressing the agouti gene 
may be predicted to inhibit de novo lipogenesis and thereby attenuate the obesity 
characteristic of these animals. The present study was conducted to evaluate this 
possibility, and we demonstrate herein that Ca2+ channel blockade reduces FAS mRNA 
levels and activity and decreases adipose tissue mass in the transgenic mice which 
ubiquitously overexpress agouti. 
C, Material and Methods 
Animals and diets: Transgenic mice were generated as previously described (8). In 
short, transgenic mice were made by pronuclear microinjection of a J3-actin promoter­
agouti transgene into FVB/N single cell embryos and maintained on the FVB/N 
background. Prior to being placed on the experimental diets, 7-week-old male transgenic 
and control mice were acclimatized on a powdered diet (Mouse Diet 5015, PMI Feeds, � 
11 % fat w/w) for 1 week. They were then randomly assigned to either a control or 
nifedipine (Sigma, St. Louis, MO) (lg/kg diet) diet and were fed ad libitum for 30 days. 
On day 27, food was held overnight for 12 hr fasting and blood was collected from the tail 
vein for glucose determination, followed by refeeding. On day 30, animals were 
anesthetized with sodium pentobarbital (50 mg/kg body weight) (Abbott Lab. North 
Chicago, IL) and blood was obtained by cardiac puncture for blood glucose and plasma 
triglyceride and insulin determination. Fat pads ( epididymal, perirenal, retroperitoneal, 
inguinal, and subscapular fats) and skeletal muscles (gastrocnemius muscles) were 
dissected, immediately weighed, frozen in liquid nitrogen, and stored at -80 °C. FAS 
activity and mRNA levels were measured in adipose tissues as described below. 
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Core temperature: Core temperature was used as an indirect metabolic index to 
determine if (a) thermogenesis is decreased in transgenic mice overexpressing agouti, and 
(b) ifnifedipine treatment increases core temperature. Temperature was measured weekly 
via a thermocouple (Columbus Instr. Columbus, OH). The probe was inserted a constant 
distance ( 1.8  ems) into the rectum of animal . After stabilization (IO sec), the temperature 
was recorded every 5 sec for 30 sec. All temperature measurements were made between 
9:00-10:30 A.M . .  
Blood glucose and plasma insulin and triglyceride analysis : Fasted and fed Blood 
glucose was measured using blood glucose monitoring system (Milpitas, CA). Plasma 
triglyceride levels were measured spectrophotometrically using an enzyme-based assay kit 
(Sigma, St. Louis, MO), and plasma insulin levels were measured by radioimmunoassay 
kit (INCST AR, Stillwater, MN). 
Fatty acid synthase activity: Fatty acid synthase activity was measured by a 
modification of the spectrophotometric method (16). Subcutaneous adipose tissue were 
sonicated (I  :3 w/v) in 250 mM sucrose buffer containing I mM EDT A (Gibco, 
Gaithersburg, MD), I mM dithiothreitol and I 00 µM phenylmethylsulfonyl fluoride 
(Sigma, St. Louis, MO) (pH 7.4). Homogenates were centrifuged at 14,000 x g for 15 
min ( at 4 °C), and the supematants were used for enzyme assays. Assays were started by 
the addition ofmalonyl CoA, and enzyme activities were expressed as nmol NADPH 
oxidized/min/mg of protein. Protein was determined by the modified method of Lowry 
using bovine serum albumin as a standard (17). 
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Dot blot analysis: Total cellular RNA was extracted by cesium chloride density 
gradient method (13). cDNA probes for FAS (pFAS7, cloned by Dr. J. W. Porter's group 
and kindly provided by Dr. A. G. Goodridge) were radiolabeled by the random primer 
method. Dot blot analysis using 1, 3, and 5 µg RNA was performed by a modification of 
the method of Meyuhas et al. (18). Total RNA was placed in eppendorftube, brought to 
50 µI with ice-cold water, added 30 µ1 20 x SSC and 20 µ1 37 % formaldehyde, and 
incubated at 65 °C for 10 min. Samples were spotted into nylon membranes (NEN, 
Wilmington, DE) in a vacuum dot-blot apparatus, rinsed with 4 x SSC, and air dried. The 
membranes were hybridized with radiolabeled FAS probe as described previously ( 19). 
Following visualization and quantitation, the membranes were stripped and reprobed with 
J3-actin as a loading control, and data are expressed as FAS : actin ratio. Visualization and 
quantitation were conducted using Ambis 4000 direct J3-counting and imaging system. 
Statistical analysis: All data were presented as mean ± standard error for four 
groups of mice; control mice on control diet, control mice on nifedipine diet, transgenic 
mice on control diet, and transgenic mice on nifedipine diet. Data were analyzed via two­
way ( diet x animal) analysis of variance or, in cases where only two groups were being 
compared, by student t test. 
D. Results 
At study initiation (8 weeks of age), the transgenic mice (n = 12) exhibited 
significantly higher body weight than the control mice (n = 10) (30.54 ± 0.66 vs. 27.26 ± 
0.28 g; p < 0.001). The increased body weight of the transgenic mice was maintained 
over the 30 days on diet, and nifedipine was without effect in both groups (Fig. 8). The 
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Figure 8. Weight gain of transgenic (Tg/-) and control (+/+) mice in either control or 
nifedipine diet. Average weights in grams are plotted over the 30 days of experiment. 
Data are reported as mean ± SE. o; control mice on control diet (n = 5), x; control mice 
on nifedipine diet (n = 5), D; transgenic mice on control diet (n = 6), �; transgenic mice on 
nifedipine diet (n = 6) 
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transgenic mice also exhibited an approximately 2-fold increase in fat pad mass (both 
visceral and subcutaneous) compared to the control mice (2.62 ± 0.27 vs. 1.21 ± 0.19 g; p 
= 0.002). However, nifedipine treatment resulted in a significant reduction in fat pad 
weight, compared to control diet (1.81 ± 0.14 vs. 1.58 ± 0.23 g, p < 0.001 in visceral 
[ epidydimal, perirenal and retroperitoneal] fat; 0. 81 ± 0 .14 vs. 0. 62 ± 0 .1 g, p = 0. 02 in 
subcutaneous [inguinal and subscapular] fat) in the transgenic mice, but was without effect 
in the control mice. The total weight of the five fat pads measured was decreased by 16 % 
in the nifedipine-treated transgenic animals (p < 0.007). Fat pad weight expressed as % 
of body weight is shown in Fig. 9. Gastrocnemius muscle ( an indicator of skeletal muscle 
mass) weight was not different between control and transgenic mice (data not shown); 
however, nifedipine treatment significantly increased gastrocnemius muscle weight by 11 
% compared to the control diet (0.284 ± 0.005 vs. 0.253 ± 0.005 g; p = 0.0009) in the 
transgenic mice, and was without effect in the control mice. When expressed as % of 
body weight, gastrocnemius muscle weight follows similar trends, as shown in Fig. 10. 
This combination of reduced fat pad mass and increased muscle mass may explain the lack 
of nifedipine effect on body weight in the transgenic mice. 
At 8 weeks of age, the transgenic mice had a O. 81 °C lower core temperature than 
the control mice (Fig. 11 ), indicating decreased thermogenesis in these animals. 
Nifedipine treatment selectively increased core temperature in the transgenic mice by 0.62 
°C (38.13 ± 0.24 to 38.75 ± 0.22 °C; p = 0.02) at day 16 of treatment, but this effect did 
not persist until the end of the experiment. 
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Figure 9. The effect of nifedipine treatment (30 days) on fat pad weights in transgenic 
(Tg/-} 1 and control (+/+)2 mice. Average of the total amount of visceral fat pads 
( epididymal, perirenal, and retroperitoneal fat) and subcutaneous fat pads (inguinal and 
subscapular fat) is expressed as % of body weight . Data are reported as mean ± SE. *p < 
0.007 vs. control mice on the same diet, ··p < 0.007 vs. transgenic mice on control diet 
1n = 5 in control diet and n = 6 in nifedipine diet, 2n = 4 in both diets 
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Figure IO. The effect of nifedipine treatment (30 days) on gastrocnemius skeletal muscle 
weight in transgenic (Tg/-) 1 and control ( +/+ )2 mice. Average weight of gastrocnemius 
skeletal muscle is expressed as % of body weight. Data are reported as mean ± SE. 
*p < 0.02 vs. control mice on the same diet 
1n = 5 in control diet and n = 6 in nifedipine diet, 2n = 4 in both diets 
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Figure 1 1 .  The basal (day 0) core temperature in transgenic (Tg/-) 1 and control (+/+)2 
mice at 8 weeks of age. Data are reported as mean ± SE. • p < 0.0005 
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To test the role of de novo fatty acid synthesis in agouti-associated obesity, we 
measured the activity off AS in adipose tissue. The transgenic mice exhibited a 7.2-fold 
increase in FAS activity in subcutaneous adipose tissue compared to the control mice, 
while nifedipine treatment completely prevented this stimulation off AS activity (Fig. 12). 
Similarly, there was a modest decrease in FAS mRNA levels in visceral adipose tissue of 
the transgenic mice treated with nifedipine compared to that of the transgenic mice on the 
control diet (Fig. 13) . 
The transgenic mice had approximately 2-fold higher fed plasma insulin levels than 
the control mice (p < 0.05) (Table 5). Nifedipine treatment completely blocked the 
hyperinsulinemia in the transgenic mice, but was without effect on the control mice (Table 
5). Nifedipine treatment also improved insulin sensitivity, as manifested by the fall in 
plasma insulin to glucose ratio in the transgenic mice (p < 0.05) (Table 5). Nifedipine 
treatment was without effect on blood glucose levels in either fasted or fed mice. There 
was also no effect of nifedipine on fasted plasma triglyceride contents (Table 5). 
E. Discussion 
Ca2+ channel antagonism with nifedipine resulted in a reduction of fat pad mass in 
the transgenic mice accompanied by an increase in skeletal muscle mass. This suggests 
that [Ca2+]i may modulate the flow of energy between storage in adipose tissue and its use 
for muscle accretion. This concept is supported by the observation that the reduction in 
core temperature in the transgenic mice was partially corrected with nifedipine treatment, 
although this correction was not sustained beyond two weeks. The reason for the 
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Figure 12. The effect of nifedipine treatment (30 days) on fatty acid synthase activity in 
subcutaneous (inguinal and subscapular) adipocytes of transgenic (T g/-) 1 and control 
( +/+ )2 mice. Enzyme activity is expressed in nmol NADPH oxidized/min/mg of protein. 
Data are reported as mean ± SE. • p = 0.009 vs. control mice on the same diet 
1n = 5 in control diet and n = 6 in nif edipine diet, 2n = 4 in both diets 
1 27 
0.9 
C 0.8 
0.7 * 
0.6 
0.5 
0.4 Cl) 
·- 0.3 
t 0.2 -
0.1 1L 
0 
Control Nifedipine 
Figure 13. The effect of nifedipine treatment (30 days) on fatty acid synthase mRNA 
levels in visceral ( epidydimal, perirenal and retroperitoneal) adipocytes of transgenic (T g/­
) mice. Total RNA was extracted from visceral adipose tissue of transgenic mice either on 
control or nifedipine diet, and analyzed by dot blot as described in methods and materials. 
Data were not available from the control mice due to the limiting quantities of adipose 
tissue available from those lean animals. Data obtained from the direct P-counting 
imaging system are normalized to RNA levels for P-actin. Data are reported as mean ± 
SE. * p = 0.04, n = 5 
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Table 5 .  Blood glucose and plasma insulin and triglyceride levels 
Animal Control 
Treatment Control 1 Nifedipine 1 
Glucose (mg/dL) (fasted) 12 1 .3 ± 6.5 125.3 ± 7.8 
(fed) 243 .0 ± 7.6 2 13 .8  ± 1 8.6 
Insulin (ng/mL) (fed) 14.96 ± 5.3 16.74 ± 8.69 
Insulin/Glucose (fed) 0.06 ± 0.02 0.084 ± 0.05 
Triglyceride (mg/dL)(fasted) 1 07 ± 14.2 83 .4 ± 20. 1 
Values are the mean ± SE. Data were compared in a row. 
1n = 4 
2n = 
5 3n = 6 
•p < 0.05 vs. control mice on the same diet 
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Transgenic 
Control2 Nifedipine3 
1 1 5 .5 ± 8.9 1 00.4 ± 1 5 .2  
230.6 ± 21 .6 235 .8  ± 9.7 
32.39 ± 4.9· 1 3 .40 ± 1 .96 
0. 140 ± 0.02· 0.057 ± 0.01  
76.5 ± 1 1 .6 62.8  ± 5.6 
transient nature of this core temperature elevation is not clear, although it may be 
developmentally related, as the nif edipine intervention was initiated well after a stable 
decrease in core temperature was apparent in the transgenic animals. 
FAS is a multifunctional enzyme that carries all of the 7 reactions involved in the 
synthesis of long chain saturated fatty acid (palmitate) from acetyl CoA and malonyl Co A 
(20). FAS protein concentration closely parallels its enzyme activity and is highly sensitive 
to nutritional and hormonal states (20-23). Fasting or high fat diet causes a dramatic 
suppression of FAS synthesis, while refeeding or high carbohydrate diet, especially 
glucose, markedly increases FAS synthesis (25-27). Several hormones, including insulin, 
stimulate FAS expression and activity, while glucagon and cAMP suppress them (28). An 
insulin response element has been in the FAS promoter region (29, 30), and chronic 
hyperinsulinemia induces an increase in FAS mRNA levels and activity in both rat liver and 
white adipose tissue (27). Moreover, obese Zucker rats have been reported to 
overexpress FAS mRNA in adipose tissue (31 ). 
Nifedipine treatment normalized both FAS mRNA levels and activities and plasma 
insulin levels in the transgenic mice. The mechanism of the insulin lowering effect of 
nifedipine is not clear. However, since an increase in Ca1• is a signal for P-cell insulin 
secretion (32), and several Ca1• antagonists (such as verapamil, nifedipine, nitrendipine, 
and other dihydropyridines) have been found in vitro to induce a dose-related reversible 
inhibition of insulin release (33), it is possible that agouti-induced Ca2• influx may 
stimulate J3-cell insulin release, and that this effect is blocked by nifedipine. Alternatively, 
reduction in circulating insulin with nifedipine may be simply due to an improvement in 
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insulin sensitivity in these mice, as manifested by the fall in the plasma insulin to glucose 
ratio (Table 5). Similarly, clinical studies have demonstrated that Ca1+ channel blockers, 
including nitrendipine and diltiazem, induce a reduction of fasting serum insulin levels 
without changing fasting serum glucose and improve insulin sensitivity in obese 
hypertensive men and women (34, 35). Furthermore, an anti-obesity effect of Ca1+ 
channel antagonists has been reported in rodents (36, 3 7), even though the mechanism was 
not clear. Therefore, it is difficult to distinguish the nifedipine effect on the primary 
genetic lesion from secondary phenotypic abnormalities, such as hyperinsulinemia in the 
transgenic mice. 
We have recently demonstrated that agouti stimulates FAS activity in a [Ca1+]i­
dependent fashion (13). Accordingly, it may be inferred that our observations of reduced 
FAS mRNA levels and activity and reduced adiposity in the transgenic mice on nifedipine 
diet result from inhibition of agouti stimulation of FAS expression. However, since the 
nifedipine treatment also normalized the hyperinsulinemia found in the transgenic mice, the 
reduction in circulating insulin is likely to have also contributed to the decrease in FAS 
activity and body fat. Indeed, it is likely that this anti-obesity effect of nifedipine may have 
resulted both from inhibition of agouti-induced Ca2+ influx in adipocytes and from the 
hypoinsulinemic effect, as we have found agouti and insulin to exhibit synergistic effects in 
stimulating FAS gene transcription (unpublished observation). 
Several studies have identified Ca2+ regulatory elements that may mediate either 
negative or positive regulation of gene transcription by Ca2• (38, 39). Therefore similar 
mechanisms may be involved in regulation of FAS gene transcription by Ca1• and agouti. 
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Alternatively, it is also possible Cal• and agouti may affect FAS transcription in an indirect 
way, perhaps, though stimulation or inhibition of other genes in their target tissues. For 
example, an accumulation of [Ca2.]i inhibits the lipoprotein lipase expression in adipocytes 
( 40), thereby decreasing fatty acid entry from triglyceride-rich-lipoprotein. This may also 
result in FAS suppression, as fatty acids are potent inhibitors of FAS gene expression ( 41-
43). 
In conclusion, data from the present study demonstrate that antagonism of Cal• 
influx may prevent agouti-mediated de novo lipogenesis and insulin resistance and thereby 
attenuate the increase in adiposity associated with dominant agouti mutations . 
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CONCLUSIONS 
Obesity is strongly associated with the development of insulin resistance and type 
II diabetes, and a causal relationship between obesity and the subsequent development of 
glucose intolerance and insulin resistance is generally accepted ( see literature review for 
references). Moreover, both obesity and insulin resistance are significant risk factors for 
the development of hypertension and coronary heart disease. This obesity syndrome 
imposes an enormous burden on the health care system. However, its extremely complex 
pathophysiologic nature and variable genetic mode of the penetrance of this disease has 
resulted in slow progress regarding the understanding mechanism. However, studies 
presented here support the hypothesis that altered [Ca2+]i metabolism is related to the 
pathogenesis of obesity and insulin resistance, thereby providing a potential target for the 
subsequent development of intervention. 
Laboratory animals, especially single-gene mutations, have played an important 
role for understanding the pathophysiology of multifactorial human disease. In the field of 
obesity research, the cloning of the agouti gene provided an exciting opportunity not only 
for elucidation of the mechanism of obesity characteristic of dominant agouti mutation, 
but also for understanding the control of normal cellular energy metabolism. Based on the 
data from the present study, Ca2+ appears to play an important role in energy metabolism 
and the ability of the agouti protein to influence [Ca2+]i levels or activate Ca2+ channels 
appears to be responsible for efficient conversion of metabolic energy into fat in viable 
yellow mice. This agouti-mediated acceleration of fat depot storage appears to be, at least 
partially, via Ca2+ activation of fatty acid synthase (FAS) transcription. 
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Further studies of the precise role of Ca2+ in regulating FAS will contribute to 
understand the mechanism by which agouti protein stimulates adipocyte fat accumulation. 
The anti-adiposity effect of Ca2+ channel inhibitor in agouti-induced obesity observed in 
this study will be further clarified when tissue specific Ca2+ channel blockers are developed 
in order to distinguish between the potential roles of agouti-induced insulin secretion 
versus direct agouti-induced lipogenesis. The only well characterized function of agouti, 
regulation of mouse coat color, is based upon competitive antagonism of a-melanocyte 
stimulating hormone (a-MSH) binding. However, data from the present study indicate 
that agouti modulation of [Ca2+]i signaling is not based upon such an antagonism, but may 
be dependent upon a non-competitive interaction with one or more melanocortin 
receptor(s). This proposed relationship is summarized in Fig. 14. Nonetheless, in vivo 
studies of the effects of a-MSH and other melanocortins in animals exhibiting the obesity 
phenotype characteristic of dominant agouti mutations are still necessary to determine the 
potential role of melanocortin antagonism in agouti-induced obesity. 
The present study may be viewed one step toward bridging the gap between 
molecular biology and genetics and physiology. Virtually, all of the currently known 
single genes causing obesity in mice, including agouti (AY, Aiapy, A;y, A6Y, and A"), obese 
(ob), diabetes (db), fat (fat), and tubby (tub), have recently been cloned, providing a new 
opportunity to couple genetic and functional analysis to physiology of tools in the field of 
obesity research. Using this with each of those mutation is anticipated to provide multiple 
therapeutic targets and opportunity for intervention in obesity. 
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Agouti 
Mel 
Ca2+ -Channel 
, [cAMP] 
• Decreased lipolysis • Increased lipogenesis (Adipose tissue) 
• Insulin resistance (Skeletal muscle) 
• Vasoconstriction (Vascular smooth muscle) 
Figure 14 .  Proposed model for agouti action. Agouti may (a) inhibit melanocortin 
receptor binding or exert direct effects on (b) melanocortin receptors of ( c) Ca2+ 
channel(s). There is proposed G-protein linkage (d) between a melanocortin receptor and 
a Ca2+ channel, such that binding of a agouti modulates the activity of the partnered 
receptor. 
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